WKN: 634814 - LIFESTREAM TECHNOLOGY INC. - 500 Beiträge pro Seite

[Inkmarker]

Die Thread soll dazu dienen, die Aktie bekannt zu machen und über sie zu diskutieren.


Zu Beginn deshalb die letzte Empfehlung des obb vom 11.12.2003.


+++ OBB-Update +++ Donnerstag, den 11. Dez. 2003

Sehr geehrte Leserinnen und Leser,

alles andere als erfolgreich war die bisherige Kursentwicklung unserer Empfehlung für Lifestream Technologies Inc. ( ISIN US53219K1016 / OTC BB: LFTC). Empfohlen am 8. September bei 0,20 Euro stand die Aktie nur kurze Zeit später massiv unter Abgabedruck und halbierte binnen zwei Monaten ihren Wert. Für viele Anleger, die unserer Empfehlung gefolgt und teilweise zu deutlich höheren Kursen eingestiegen sind und nun auf massiven Verlusten sitzen, stellt sich nun die Frage, wie man sich weiter verhalten sollte, insbesondere, da eine von US-Präsident Bush anfangs dieser Woche unterschriebene Reformmaßnahme bezüglich der Früherkennung und exakten Erfassung von Cholesterinerkrankungen einen leichten Hoffnungsschimmer für die Aktie bedeutet. Lesen Sie nachfolgend Hintergrundinformationen zum Kurssturz der vergangenen Wochen sowie unsere Einschätzung zu den aktuellen News und deren Einfluss auf den weiteren Kursverlauf von Lifestream Technologies.


Lifestream Technologies Inc. (ISIN US53219K1016 )


+++ Hintergrundinformationen zum Kurssturz sowie aktuelle News +++


Unternehmensprofil:



Das 1994 gegründete Healthcare-Unternehmen entwickelt und vertreibt eine Produktlinie von kleinen Geräten, sogenannten Cholesterin-Monitoren, mit denen der Cholesterinspiegel überwacht werden kann. Das Hauptaugenmerk liegt dabei auf der Entwicklung des ersten Cholesterin-Monitors, der über ein integriertes Smart-Card-Lesegerät verfügt. Revolutionär an dieser Technologie ist dabei, dass dieses Gerät nicht nur in Arztpraxen und Krankenhäuser Verwendung findet, sondern aufgrund seiner handlichen Größe in erster Linie für den Gebrauch zu Hause konzipiert wurde. Die Vorzüge liegen dabei auf der Hand: Der Anwender ist durch dieses einfach zu handhabende Gerät in der Lage, kostengünstig und regelmäßig Cholesterinmessungen durchzuführen. Eine enorme Erleichterung für die Patienten, die mit einem erhöhten Cholesterinspiegel zu kämpfen haben, der aus medizinischer Sicht der regelmäßigen Überwachung bedarf, um Herzbeschwerden vorzubeugen. Wirtschaftlich bedeutet die Anwendbarkeit von zu Hause aus eine enorme Kosteneinsparung, die übertragen auf die Vielzahl von Cholesterinkranken allein in den Vereinigten Staaten ein enormes Marktpotenzial birgt. Der Cholesterincheck wird damit genauso einfach, wie das tägliche Wiegen oder das Blutdruckmessen.


ISIN: US53219K1016

aktueller Kurs: 0,12 EUR

Kursziel: 0,20 EUR

Widerstand: 0,15 EUR

Stopp-Kurs: 0,08 EUR

halten!



Aktuelles / Weitere Einschätzung:


Einer der Hauptgründe für den massiven Kursverfall während der vergangenen Wochen war zweifellos das überraschende Delisting von der American Stock Exchange (AMEX). Lifestream selbst betonte dabei jedoch, dass das Delisting vom Unternehmen selbst veranlasst wurde und keinesfalls eine Zwangsmaßnahe der Börse darstellte. Begründet wird das Delisting dabei mit dem momentan strikten Kostensenkungsprogramm des Unternehmens, das sich nicht mehr mit den hohen Kosten eines Listings an der AMEX vereinbaren lässt. Diese Maßnahme wurde nach umfassender Abwägung für notwendig erachtet, auch wenn Lifestream nach wie vor von der Qualität der AMEX überzeugt ist und ein erneutes Listing zukünftig nicht ausschließt. Die Einsparungen sollen nun verstärkt in laufende und geplante Marketingkampanien investiert werden, um die Marktposition weiter zu stärken. Für den Anleger gilt es nun zu beachten, dass die Aktie nicht mehr unter dem alten Symbol KFL, sondern nun an der OTC BB unter dem Symbol LFTC notiert ist. Nach dem kontinuierlichen Abwärtstrend der letzten Wochen, könnte sich das Blatt nun jedoch wenden. Anfang dieser Woche legte die Aktie kräftig zu und gewann unter deutlich anziehenden Handelsumsätzen in der Spitze bis zu 35%. Profitieren konnte die Lifestream-Aktie dabei von Reformmaßnahmen im Gesundheitssektor, die US-Präsident Bush abgesegnet hat. Hintergrund dabei ist die enorme Zahl an Cholesterinpatienten, die sich zum Teil nicht über ihre Erkrankung und den damit verbundenen gesundheitlichen Risiken, insbesondere für das Herz, bewusst sind, präzise zu erfassen, um ihnen dann eine entsprechende gesundheitliche Versorgung zukommen zu lassen. Dies rückt eine Vielzahl von Unternehmen aus dem Gesundheitssektor und insbesondere Lifestream, mit ihrem innovativen Cholesterin-Monitoren, in den Blickpunkt der Anleger und sorgt auch weiterhin für Kursfantasie. Vorerst ist es der Aktie damit gelungen, sich von den Tiefständen bei 0,09 Euro zu entfernen. Mit akt. 0,12 Euro befindet sich der Titel nun an einer charttechnisch wichtigen Marke, an der der 38-Tage-Durchschnitt verläuft. Gelingt ein Ausbruch über diesen Widerstand, könnte es der Aktie gelingen, schnell weitere Verluste wettzumachen. Obwohl wir bei der Festlegung der bisherigen Stopp-Loss-Marke bei 0,09 Euro und damit exakt am Tiefpunkt kein glückliches Händchen bewiesen haben, empfehlen wir denjenigen, die ihre Aktien noch im Depot haben, mit einem Stopp-Loss bei 0,08 Euro abzusichern und diese vor dem Hintergrund der positiven News der letzten Tage zu halten. Unser Kursziel setzen wir vorerst auf 0,20 Euro und damit auf unseren ursprünglichen Empfehlungskurs. Langfristig sind wir nach wie vor von der Aktie überzeugt und sehen deutlich höheres Kurspotenzial.




Ihr Team vom OBB !


Weitere Informationen und aktuelle Meldungen demnächst.


Grüße

Inkmarker

[millionenklick]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Inkmarker]

Gewisse User sollte man einfach nicht beachten !

Userinfo

Username: millionenklick
Registriert seit: 03.04.2004
User ist momentan: Online seit 03.04.2004 20:24:47
Threads: 0
Postings: 1 [ Durchschnittlich 167,1180 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen
Interessen: keine Angaben


Traurig aber wahr.

[mounteverest]

Lifestream ist sogar Marktführer

[Inkmarker]

Nachdem die Fa. kurz vorgestellt wurde, werden sich einige fragen, warum es zu einem derartigen Kursverfall in den letzten Monaten kam und ob es weiter nach unten geht.

Da wir alle keine Glaskugel besitzen, kann man also nur mutmaßen.


M.E. hängt der Kursverfall mit folgender Meldung zusammen:

LFTC: Seeks Vote; Increase Authorized Shares 250M to750M

THURSDAY , MARCH 18, 2004 02:59 PM

According to a PRE 14A filed today, a Special Meeting of Stockholders of Lifestream Technologies, Inc. (OTCBB: LFTC) may be held at Red Lion Templin`s Resort located at 414 East First Avenue, Post Falls, Idaho, on April 28, 2004, at 12 NOON ET, to approve an amendment to the Articles of Incorporation to increase the number of authorized shares of Common Stock from 250,000,000 shares to 750,000,000 shares.

Diese Meldung besagt, dass LFTC plant das genehmigte Kapital von 250.000.000 Aktien auf 750.000.000 zu erhöhen. Zu diesem Zweck soll am 28.04.2004 eine Abstimmung der Aktionäre stattfinden.


Die Frage die sich stellt ist m.E. nicht, ob die Genehmigung erteilt (wohl ja), sondern wofür die Aktien gebraucht werden.

Meine Meinung dazu im nächsten Beitrag.


Bis dahin viele Grüße

Inkmarker

[Inkmarker]

An dieser Stelle nochmal Danke an die Verantwortlichen von wo die den unqualifizierten Beitrag des Users milionenclick (Werbung) herausgenommen haben.

[Inkmarker]

Hallo Leute!

Hier LFTC-filing vom 02.04.2004 (mit freundlicher Unterstützung von mounteverest):


Ich habe es bisher nur teilweise übersetzen können. Es geht im Wesentlichen um die anstehende Abstimmung und die Verwendung der Aktien zur Ausgabe an institutionelle Investoren zur Schuldentilgung (nach meinem Verständnis - ohne Gewähr für die Richtigkeit der Übersetzung).


SCHEDULE 14A
INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14 INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES EXCHANGE ACT OF 1934


Filed by the registrant [X]
Filed by party other than the registrant [_]


Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12



LIFESTREAM TECHNOLOGIES, INC.
(Name of Registrant as Specified in Its Charter
and of Person Filing Proxy Statement)


Payment of Filing Fee (Check the appropriate box):

[X] No fee required
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transactions applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11:
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0- 11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement no.:
(3) Filing Party:
(4) Date Filed:




LIFESTREAM TECHNOLOGIES, INC.
510 Clearwater Loop, Suite 101, Post Falls, Idaho 83854

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD APRIL 28, 2004

To our Stockholders:

You are cordially invited to attend a Special Meeting of Stockholders
(hereinafter, "the Special Meeting") of Lifestream Technologies, Inc.
(hereinafter, "the Company"), a Nevada corporation, which will be held at Red
Lion Templin`s Resort located at 414 East First Avenue, Post Falls, Idaho, on
April 28, 2004, at 9:00 a.m., Pacific Time, or at any and all adjournments
thereof. The sole purpose of the Special Meeting is to approve an amendment (the
"Amendment") to the Articles of Incorporation to increase the number of
authorized shares of Common Stock from 250,000,000 shares to 750,000,000 shares.

This matter is more fully discussed in the Proxy Statement accompanying this
Notice. We believe the approval of this Amendment is imperative in view of the
Company`s financial condition and operational needs and its consequent need for
additional authorized shares for the purpose of obtaining additional financing.

The Board of Directors of the Company has unanimously determined that the
proposed Amendment is advisable and in the best interests of the Company and
recommends that you vote FOR the Amendment.

The Board has fixed the close of business on March 04, 2004, as the record date
for determining those stockholders who will be entitled to notice of, and to
vote at, the Special Meeting. The stock transfer books will not be closed
between the record date and the date of the meeting.

Approval of the proposed Amendment requires the affirmative vote of at least a
majority of the outstanding shares of the Company`s Common Stock, whether
present in person or represented by proxy. Accordingly, it is important that
your shares be represented at the meeting. THE PROMPT RETURN OF PROXIES WILL
SAVE YOUR COMPANY THE EXPENSE OF FURTHER REQUESTS IN ORDER TO OBTAIN THE
NECESSARY APPROVAL. WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, PLEASE
COMPLETE, DATE AND SIGN THE ENCLOSED PROXY CARD AND RETURN IT IN THE ENCLOSED
ENVELOPE. Your proxy may be revoked, in writing, at any time prior to the time
it is voted. You may also revoke your proxy by attending the meeting and voting
in person.

Please read the proxy materials carefully. Your vote is important and the
Company appreciates your cooperation in considering and acting on the matters
presented.

Very truly yours,


/s/ Christopher Maus
-----------------------------------------------------
Christopher Maus, Chairman of the Board of Directors,
President and Chief Executive Officer
Post Falls, Idaho
April 2, 2004




STOCKHOLDERS SHOULD READ THE ENTIRE PROXY STATEMENT
CAREFULLY PRIOR TO RETURNING THEIR PROXIES

PROXY STATEMENT FOR A SPECIAL MEETING OF STOCKHOLDERS OF
LIFESTREAM TECHNOLOGIES, INC.
TO BE HELD APRIL 28, 2004

This Proxy Statement is furnished in connection with the solicitation by the
Board of Directors (hereinafter, the "Board") of Lifestream Technologies, Inc.
(hereinafter, the "Company"), a Nevada corporation, of proxies to be voted at a
Special Meeting of Stockholders (hereinafter, "the Special Meeting") to be held
at Red Lion Templin`s Resort located at 414 East First Avenue, Post Falls, Idaho
on April 28, 2004, at 9:00 a.m. Pacific Time or at any and all adjournments or
postponements thereof, for the purpose set forth in the accompanying Notice of
Special Meeting of Stockholders (hereinafter, "the Notice"). This Proxy
Statement and the proxy card will be first mailed to Stockholders on or about
April 5, 2004.

VOTING RIGHTS AND SOLICITATION

The close of business on March 04, 2004, was the record date for stockholders
entitled to notice of, and to vote at, the Special Meeting. As of that date,
154,675,276 shares of the Company`s Common Stock, $0.001 par value per share
(hereinafter "the Common Stock"), were issued and outstanding. The Company did
not have any other class of equity securities outstanding as of the record date.
All shares of the Company`s Common Stock outstanding on the record date are
entitled to vote at the Special Meeting, and stockholders of record entitled to
vote at the Special Meeting will have one vote for each share so held on the
matter to be voted upon.

There will not be any matters presented at the Special Meeting other than the
proposal set forth in this Proxy Statement and accompanying Notice. Any
stockholder has the right to revoke his or her proxy at any time before it is
voted by either delivering to the Company at its principal executive offices at
510 Clearwater Loop, Suite 101, Post Falls, Idaho 83854, Attn: Chief Financial
Officer, a written notice of revocation or duly executed proxy bearing a later
date or by attending the Special Meeting and voting in person.

Approval of the proposed Amendment will require the affirmative vote of a
majority of the outstanding shares of Common Stock, cast by the Stockholders
entitled to vote, in person or by proxy. Broker non-votes and abstentions will
have the effect of a vote against the proposal being submitted for stockholder
approval.

The cost of this solicitation will be borne by the Company. Proxies will be
solicited principally through the use of the mail, but, if deemed desirable, may
be solicited personally or by telephone, electronic mail, telegraph, or personal
interview by directors, officers and employees of the Company for no additional
compensation. Arrangements may be made with brokerage houses and other
custodians, nominees and fiduciaries to send proxies and proxy material to the
beneficial owners of the Company`s Common Stock, and such persons may be
reimbursed for their expenses.

QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND THE SPECIAL MEETING

WHY ARE WE CALLING THIS SPECIAL MEETING?
To approve an amendment to the Company`s Articles of Incorporation to
increase the number of authorized shares of Common Stock from 250,000,000 to
750,000,000.

WHO IS ENTITLED TO VOTE AT THE MEETING?
Stockholders of record of Common Stock at the close of business on
March 4, 2004 may vote at the meeting. On March 04, 2004, 154,675,276 shares of
Common Stock were outstanding and eligible to vote.

WHAT IS THE DIFFERENCE BETWEEN A SHAREHOLDER OF RECORD AND
A "STREET NAME" HOLDER?
If your shares are registered directly in your name with Nevada Agency
& Trust Company, our transfer agent, you are considered the shareholder of
record of those shares.
If your shares are held in a stock brokerage account or by a bank or
other nominee, you are considered the beneficial owner of these shares, and your
shares are held in "street name."

1



HOW DO I VOTE MY SHARES?
If you are a shareholder of record, you can give a proxy to be voted at
the meeting by mailing the enclosed proxy card.
If you hold your shares in "street name," you must vote your shares in
the manner prescribed by your broker or nominee. Your broker or nominee has
enclosed or provided a voting instruction card for you to use in directing the
broker or nominee how to vote your shares.

CAN I VOTE MY SHARES IN PERSON AT THE MEETING?
Yes. If you are a shareholder of record, you may vote your shares at
the meeting by completing a ballot at the meeting.
However, if you are a "street name" holder, you may vote your shares in
person only if you obtain a signed proxy from your broker or nominee giving you
the right to vote the shares.
Even if you currently plan to attend the meeting, we recommend that you
also submit your proxy as described above so that your vote will be counted if
you later decide not to attend the meeting.

WHAT IS THE RECOMMENDATION OF THE BOARD OF DIRECTORS?
The Board of Directors recommends a vote FOR the Amendment increasing
the authorized Common Stock.

WHY IS THE COMPANY SEEKING SHAREHOLDER APPROVAL FOR THE AMENDMENT?
Under Nevada law, we need shareholder approval to amend our Articles of
Incorporation to increase the number of authorized shares of Common Stock.

WILL THE COMPANY BE SUBJECT TO ANY IMMEDIATE ADVERSE EFFECTS IF THE AMENDMENT IS
NOT APPROVED?
We require additional authorized common shares to enable us to issue
our common stock (a) under our existing stock option plans, (b) upon full
exchange of certain outstanding debentures and the exercise of related stock
purchase warrants, (c) upon conversion of certain outstanding convertible
promissory notes, (d) in the event of exercise of an option to purchase $1.22 in
additional convertible debentures and the exercise of related stock purchase
warrants, and (e) as consideration in connection with future financings that we
may agree to. In the event that stockholders do not authorize the Amendment, we
will be unable to meet the foregoing contingencies, we may be in default of
certain contractual obligations, and, ultimately, we may be forced to curtail or
cease operations. Our Board of Directors believes that it is critical to our
continued viability that we authorize additional common stock for the foregoing
purposes and to continue to implement our current business and marketing
strategies.

WHAT IF I DO NOT SPECIFY HOW I WANT MY SHARES VOTED?
If you do not specify on your proxy card how you want to vote your
shares, we will vote them FOR the Amendment.

CAN I CHANGE MY VOTE?
Yes. You can revoke your proxy at any time before it is exercised in
any of three ways:
o By submitting written notice of revocation to our Secretary;
o By submitting another proxy by mail with a later date and, if by
mail, that is properly signed; or
o By voting in person at the meeting.

IS THE APPROVAL BY THE SHAREHOLDERS ALREADY ASSURED?
Our Board of Directors and officers as a group own or control
approximately 5.53% of our voting shares. While they have unanimously approved
and recommended the Amendment, there are no other agreements in place that would
assure shareholder approval of the Amendment.

ARE THERE ANY OTHER MATTERS TO BE ACTED UPON AT THE MEETING?
Under our bylaws, no other business besides that specified in the
Notice may be transacted at this Special Meeting.

2


SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT (1)

The following table sets forth certain information regarding the beneficial
ownership of the Company`s Common Stock as of March 4, 2004 by (i) each person
known by the Company to be the beneficial owner of more than five percent of the
outstanding shares of Common Stock, (ii) each current director, (iii) each
executive officer, and (iv) all current directors and executive officers as a
group. A person is also deemed to be a beneficial owner of any securities to
which the person has the right to acquire beneficial ownership within sixty
days. All shares are subject to the named person`s sole voting and investment
power unless otherwise indicated.


PERCENT OF
SHARES OUTSTANDING SHARES
BENEFICIALLY BENEFICIALLY
NAME AND ADDRESS OF BENEFICIAL OWNER (2) OWNED OWNED (3)
---------------------------------------- ------------ ------------------

DIRECTORS AND OFFICERS
----------------------
Christopher Maus (4) ................................... 3,467,367 2.23%

Michael Crane (5) ...................................... 3,125,391 2.02%

Robert Boyle (6) ....................................... 314,700 Less than 1%

William Gridley (7) .................................... 199,000 Less than 1%

Neil Luckianow ......................................... -0- Less than 1%

Edward Siemens (8) ..................................... 609,385 Less than 1%

Brett Sweezy (9) ....................................... 692,936 Less than 1%

Jackson Connolly (10) .................................. 251,706 Less than 1%
--------- ------------

ALL DIRECTORS AND OFFICERS AS A GROUP (8 PERSONS) (11).. 8,660,485 5.53%
--------- ------------





SHARES BENEFICIALLY PERCENT OF SHARES
NAME AND ADDRESS OF BENEFICIAL OWNER (2) OWNED BENEFICIALLY OWNED (3)
---------------------------------------- ------------------- ----------------------

OTHER BENEFICIAL OWNERS:
------------------------
RAB Europe Fund Limited (12)............................ 15,950,000 9.99%
c/o RAB Capital Limited
Attn: Phillip Richards, Director
No. 1 Adam Street
London W2CN 6LE, United Kingdom

Mercer Management (13).................................. 11,194,661 7.09%
c/o Gordon Rock
5820 East Mercer Way
Seattle, WA 98040


----------
(1) Based upon information furnished to the Company by the beneficial owners
or otherwise obtained from the stock transfer books of the Company.
(2) Unless otherwise indicated, the business address for each beneficial
owner is c/o Lifestream Technologies, Inc., 510 Clearwater Loop, Suite
101, Post Falls, Idaho 83854.
(3) Percentage of ownership is based upon 154,675,276 actual shares of Common
Stock outstanding on March 4, 2004. Shares of Common Stock subject to
stock options or warrants that are currently exercisable or will become
exercisable within 60 days after March 04, 2004, and shares of Common
Stock subject to convertible term notes that are currently convertible or
will become convertible within 60 days after March 04, 2004, are deemed
outstanding for computing the beneficial ownership percentage of the
person or group holding such options, warrants and notes, but are not
deemed outstanding for computing the percentage of any other person or
group.


3



(4) Includes 622,000 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(5) Includes 142,500 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004. Excludes 101,590 common shares held by Lochnau, Inc., a
privately held investment management corporation for which Mr. Crane
serves as Chairman of the Board of Directors, to which Mr. Crane
disclaims any beneficial ownership.
(6) Includes 122,000 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(7) Includes 72,000 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(8) Includes 408,500 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(9) Includes 393,297 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(10) Includes 146,739 shares issuable upon exercise of options that are
currently exercisable or will become exercisable within 60 days after
March 4, 2004.
(11) Includes 1,907,036 shares issuable upon exercise of options and warrants
that are currently exercisable or will become exercisable within 60 days
after March 4, 2004.
(12) RAB Europe Fund Ltd., as of March 04, 2004, owned convertible term notes
of ours that can be converted into 40,200,000 shares of our Common Stock.
RAB Europe Fund Ltd. does not have the right to convert any debt, to the
extent such conversion would cause RAB Europe Fund Ltd., together with
its affiliates, to have acquired a number of shares of our Common Stock
during the 60-day period ending on the date of conversion which, when
added to the number of shares of our Common Stock held at the beginning
of such 60-day period, would exceed 9.99% of the number of shares of our
Common Stock then outstanding. The number of shares beneficially owned by
RAB Europe Fund Ltd., in the table above, reflects this limitation.
(13) Includes 799,500 shares issuable upon exercise of options and warrants
that are currently exercisable or will become exercisable within 60 days
after March 4, 2004. Also includes 2,440,000 shares issuable upon
conversion of convertible term notes that are currently convertible or
will become convertible within 60 days after March 4, 2004.



PROPOSAL 1

APPROVAL OF AN AMENDMENT TO THE COMPANY`S ARTICLES OF INCORPORATION TO
INCREASE THE AUTHORIZED CAPITALIZATION

Our Board of Directors (the "Board") has unanimously adopted a resolution
proposing and recommending stockholder approval of an amendment to the Company`s
Articles of Incorporation which will increase the Company`s authorized number of
shares of Common Stock from 250,000,000 shares, par value $0.001 per share, to
750,000,000 shares, par value $0.001 per share. The increase in the number of
authorized Common Stock would not affect the authorized number of shares of
preferred stock, which would remain at 15,000,000 shares, none of which have
been issued. As of March 04, 2004, the Company had 154,675,276 shares of Common
Stock outstanding.

Our Board believes it is imperative that the Company`s authorized number of
shares of Common Stock be increased in order to provide sufficient authorized
but unissued Common Stock to permit the exercise of outstanding options and
warrants and the conversion of outstanding convertible debentures. The Board
also believes that the proposed amendment will provide equity for the future
financial and other needs of the Company and recommends such amendment to the
Shareholders for adoption. If the amendment is adopted, it will become effective
upon filing with the secretary of state of the State of Nevada.

BACKGROUND INFORMATION
As of June 30, 2003, we had 92,894,590 common shares issued and outstanding and
approximately 7,105,410 unissued shares available for issuance. In August 2003,
a debenture holder converted $700,000 of principal and accrued interest into 7
million common shares, leaving only 105,410 unissued shares. As discussed in our
Annual Report for the fiscal year ended June 30, 2003, and in the Management`s
Discussion and Analysis sections of our Annual Report filed with the Securities
and Exchange Commission (the "SEC") for the fiscal year ended June 30, 2003 (see
"Substantial Doubt As To Our Ability to Continue As A Going Concern"), because
of our substantial accumulated operating and net losses and our negative
operating cash flows incurred by the Company since inception, our ability to
continue as a going concern has been dependent on our obtaining additional
equity infusions or alternative financing.

4



On September 15, 2003, our Board approved the sale and issuance of $3,350,000 of
8% convertible debentures, due September 2006, and Common Stock purchase
warrants. The debentures were convertible into 25,769,231 shares of Common Stock
at $0.13 a share, and the warrants were exercisable into 12,884,615 additional
shares of Common Stock. In accordance with the purchase agreement governing this
transaction, in December 2003 our shareholders approved an amendment to our
certificate of incorporation increasing the number of authorized common shares
from 100,000,000 to 250,000,000 authorized shares.

Due to the continued decline of the price of our Common Stock and our desire to
cause investors to convert their debentures, on January 13, 2004, the Company
entered into an Exchange Agreement with each holder of its convertible
debentures that were issued in September 2003. Under the Exchange Agreement,
each debenture holder agreed, subject to a 4.99% beneficial ownership
limitation, to exchange the principal amount of its debenture for shares of the
Company`s Common Stock, at the rate of $0.09 of debenture principal per share of
Common Stock. Accrued but unpaid interest on each note was paid at the time of
the exchange by the issuance of additional shares of Common Stock at the rate of
$0.09 per share. Accordingly, in January 2004 the Company issued 34,655,011
shares of Common Stock upon exchange of debenture principal in the amount of
$2,975,624 and the payment of accrued but unpaid interest.

In December 2003, three debenture holders converted $1,279,241 of principal and
interest into 12,378,778 common shares and in February 2004 two investors
exercised previously issued Common Stock purchase warrants into 4,615,384 common
shares.

As a result of the above-described financings and other issuances of shares, we
issued approximately 62,000,000 shares of Common Stock during the period of
August 2003 through February 2004 resulting in 154,675,276 common shares
outstanding at March 4, 2004.

RECENT FINANCINGS
On February 19, 2004 we consummated the sale of $2,775,000 of convertible
debentures and Common Stock purchase warrants. In the event that the debentures
are converted at the stated conversion price of $.05 per share, we would be
required to issue approximately 55,500,000 shares of Common Stock. In the event
that the warrants are converted at the $.065 per share exercise price, we would
be required to issue an additional approximately 16,650,000. The conversion
price is subject to adjustment upon the occurrence of certain events including
stock dividends, subdivisions, combinations and reclassifications of the
Company`s Common Stock. In addition, we are required to register 125% of the
number of shares issuable upon conversion of the debentures and exercise of the
warrants. This registration requirement obligates the Company to register and
reserve for issuance a total of 90,187,500 shares upon conversion of the
debentures and exercise of the warrants. In connection with the debenture
purchase agreement, the Company agreed to seek shareholder approval to increase
the number of authorized common shares to 500,000,000.

Subject to obtaining shareholder approval to increase the number of authorized
common shares, investors in the February 19, 2004 financing have been granted
the option to purchase up to an additional $1.22 million in convertible
debentures and warrants with terms and conditions substantially identical to
those applicable to the February 19, 2004 transaction. If these debentures are
sold and converted and the related warrants are issued and exercised, we will be
required to issue an additional 42,864,865 shares of Common Stock.

In March 2004, we issued an additional $122,000 of convertible debentures from
which we received $100,000 in net proceeds after an original issue discount of
$22,000. We also issued 732,000 of detachable stock purchase warrants in
connection with this transaction. The convertible debentures and common stock
purchase warrants have identical terms and conditions to those issued on
February 19, 2004 and could be converted into 3,172,000 shares.

5



SUMMARY OF POSSIBLE ISSUANCE OF SHARES FOR EXISTING INSTRUMENTS
As of March 4, 2004, we had 154,675,276 shares of Common Stock outstanding, and
we could be required to issue up to an additional 197,020,560 shares, as
follows:


---------------------------------------------------------------------------------------------------
Shares issuable upon exercise of outstanding stock options 5,619,748
---------------------------------------------------------------------------------------------------
Shares issuable under the Company`s stock option plans upon exercise
of stock options not yet granted 3,698,926
---------------------------------------------------------------------------------------------------
Shares issuable upon exchange of remaining debentures and exercise of
warrants issued in September 2003 10,484,521
---------------------------------------------------------------------------------------------------
Shares issuable upon conversion of RAB Europe Fund Limited convertible
notes 40,200,000
---------------------------------------------------------------------------------------------------
Shares issuable upon conversion of debentures and exercise of warrants
issued in February and March 2004 75,322,000
---------------------------------------------------------------------------------------------------
Additional shares to be registered in connection with the February
and March 2004 financing to cause 125% registration coverage 18,830,500
---------------------------------------------------------------------------------------------------
Shares issuable in the event of exercise of option to purchase
$1.22 million in debentures and warrants, and the conversion and
exercise
thereof 42,864,865
----------
---------------------------------------------------------------------------------------------------
TOTAL SHARES ISSUABLE 197,020,560
===========
---------------------------------------------------------------------------------------------------


We currently are unable to repay our convertible debentures, which are due
commencing February 2006 and continuing to December 2006, and are payable in
cash. Our currently authorized shares will permit the conversion of only a
portion of these instruments. If we do not authorize additional common shares
and we do not have cash to repay the debentures at maturity, we will be in
default of the debentures, and will be subject to claims for damages. In the
absence of additional authorized shares, we are also unable to comply with the
terms of a recent financing requiring us to register 125% of the common shares
underlying the debentures and warrants issued in our February and March 2004
financings, and we will have insufficient authorized shares to permit us to
complete the additional $1.22 million in convertible debentures and warrants
which the investors in the February 19, 2004 have been granted the option to
purchase. Moreover, there is not sufficient equity available to fund any
additional equity financing for the Company.

REQUIREMENT FOR ADDITIONAL AUTHORIZED SHARES
Although the financings we have consummated provided funds necessary for the
Company to continue as a going concern and provided minimal working capital, we
continue to need substantial additional capital, either through substantial
capital infusions, periodic, smaller capital infusions or alternative
traditional financings, both to fund current operating needs pending our ability
to generate positive cash flow from operations, and to fund production of our
product and additional marketing efforts which we believe are critical to our
plan for achieving such positive cash flow from operations.

While we have issued a substantial number of shares in equity financing
transactions at a discount to the then current market price for our shares, the
capital infusion provided by such financings was not available to us from other
sources, and the capital that was provided enabled us to fund our ongoing
operational needs, our planned inventory purchases and to partially fund the
on-going marketing campaign we began in October 2003. Without that funding, we
would likely have been forced to curtail, and possibly cease, operations.

The approval of the Amendment by our stockholders cannot assure that we will be
able to raise additional funds through the issuance of stock or convertible
notes, or otherwise. However, following approval of the Amendment, and the
improvement to our financial statements and position that the recent financings
provide, we believe we will be in a position to obtain the additional financing
necessary to continue to implement our business plan. In addition to such
increased authorized stock being available for additional financing, our Board
would have the flexibility to use the additional authorized stock for any
reasonable business and financial purposes, including providing equity
incentives to consultants, employees, officers or directors, establishing
strategic relationships with other companies and expanding the Company`s
business or product lines through the acquisition of other businesses or
products. Except as set forth above, the Company has not identified particular
financings or other specific purposes for which the newly authorized shares will
be issued.

6



EFFECT ON EXISTING STOCKHOLDERS
The additional Common Stock to be authorized will have rights identical to the
currently outstanding Common Stock of the Company. Adoption of the proposed
Amendment and issuance of the Common Stock will not affect the rights of the
holders of currently outstanding Common Stock of the Company, except for the
dilutive effects incidental to issuing additional shares of Common Stock and
increasing the number of shares of Common Stock outstanding. The issuance of
additional Common Stock will have a significant dilutive effect on the ownership
interests of the Company`s existing Stockholders such as dilution to any future
net income per share and any future payment of dividends per share, if and when
the Company becomes profitable, dilution to the voting rights of current holders
of Common Stock and by potentially decreasing the market value of the Common
Stock to the extent shares are sold for a price less than the current market
value of the stock. Furthermore, the increase in the number of shares of Common
Stock available for sale in the market, particularly if we agree to register
such shares for public resale, could represent an overhang on the market and
could depress the market price of our Common Stock.

Because listing maintenance requirements on both the OTC-BB and Pink Sheets
require timely public filings of financial and other information, but do not
require shareholder approval for issuing additional shares, even if the
transactions involve the issuance of a substantial percentage of shares and such
shares are deemed to be issued at less than market price, the issuance of our
shares in connection with additional financings will generally be solely within
the discretion of the Board of Directors except in situations where Nevada
corporate law requires stockholder approval such as the issuance of stock in a
merger. Shares may be issued, in the discretion of the Board of Directors, in
connection with normal corporate financing and similar transactions without any
prior notice to Stockholders.

Holders of the Company`s Common Stock have no preemptive rights to purchase
additional shares upon issuance of additional shares by the Company. Under
Nevada law, the Company`s Stockholders are not entitled to appraisal rights with
respect to the proposed increase in the number of authorized shares.

ADDITIONAL AUTHORIZED SHARES ARE NOT SOUGHT FOR ANTI-TAKEOVER PURPOSES
Increasing the number of authorized shares of the Company`s Common Stock is not
motivated by takeover concerns and is not intended by the Board to be an
anti-takeover measure. The proposed amendment is not in response to any known
effort on the part of any party to accumulate material amounts of stock to
acquire control of us or to change our management. However, the availability of
additional authorized but unissued shares of Common Stock could enable the Board
to make it more difficult for a person or group of persons to obtain control of
the Company by a proxy or tender offer, by issuing shares in a defensive manner.
Our existing Articles of Incorporation do provide for a staggered Board of
Directors, which also may have material anti-takeover effects, however, the
proposed amendment is not part of any plan by management or the Board of
Directors to impede a takeover effort and there are no plans by management to
recommend further measures to the Board of Directors or Stockholders to
discourage tender offers or takeover attempts.

BOARD RECOMMENDATION
Our Board believes it is advisable and in the Company`s best interests to amend
our Articles of Incorporation to authorize 500,000,000 additional shares of
Common Stock which will be available to meet our current obligations under
outstanding options, warrants, convertible notes and debentures, for obtaining
additional financing and for other corporate purposes. We continue to
periodically experience a negative working capital position, which we primarily
attribute to our continued inability to finance sufficient additional inventory
to meet increased demand for our product and to fund more extensive marketing
activities to further increase the demand for our product. These were the
primary factors which our Board considered in determining the need for
additional shares of stock to enable us to acquire this necessary financing.
Although the issuance of additional shares will be dilutive to existing
Stockholders, our ability to finance our short and long-term business plans is
believed to be critical to our continued operations and, hopefully, our future
success. Accordingly, the Board recommends that you vote FOR the proposed
amendment to our Articles of Incorporation.

VOTE REQUIRED
Approval of the amendment to the Company`s Articles of Incorporation to increase
the number of the Company`s authorized shares of Common Stock requires the
affirmative vote of a majority of our issued and outstanding shares of Common
Stock. Abstentions and broker non-votes will have the effect of a vote against
the Amendment.

7


OTHER MATTERS

Only the Proposal set forth in the Notice for this Special Meeting of
Stockholders may be presented for vote at this meeting. Stockholder proposals
for the 2004 Annual Meeting of Stockholders of the Company must be received by
the Company at its principal executive offices at 510 Clearwater Loop, Suite
101, Post Falls, Idaho 83854, Attn: Chief Financial Officer, not later than July
15, 2004, for inclusion in the Proxy Statement and Proxy relating to the 2004
Annual Meeting of Stockholders.

REQUEST FOR VOTE

It is important that your shares be represented at the Special Meeting,
regardless of the number of shares that you hold. YOU ARE URGED TO PROMPTLY
EXECUTE AND RETURN THE ACCOMPANYING PROXY IN THE ENVELOPE THAT HAS BEEN ENCLOSED
FOR YOUR CONVENIENCE. Stockholders who are present at the Special Meeting may
revoke their proxies and vote in person or, if they prefer, may abstain from
voting in person and allow their proxies to be voted.

By Order of the Board of Directors,


/s/ Christopher Maus
-------------------------------------
Christopher Maus
Chairman of the Board of Directors,
President and Chief Executive Officer
April 2, 2004
Post Falls, Idaho

8



THIS PROXY IS SOLICITED BY AND ON BEHALF OF THE BOARD OF DIRECTORS
LIFESTREAM TECHNOLOGIES, INC.
PROXY - SPECIAL MEETING OF STOCKHOLDERS - APRIL 28, 2004

The undersigned stockholder of Lifestream Technologies, Inc. hereby appoints
Messrs. Christopher Maus and Robert Boyle of Lifestream Technologies, Inc., and
either of them, with full power of substitution to each, to act as
attorneys-in-fact and proxies to represent the undersigned at the Special
Meeting of Stockholders, to be held at the RED LION TEMPLIN`S RESORT LOCATED AT
414 EAST FIRST AVENUE, POST FALLS, IDAHO, ON APRIL 28, 2004, AT 9:00 a.m., local
time, and at any and all adjournments thereof, and to vote all of the shares of
Common Stock of Lifestream Technologies, Inc. which the undersigned is entitled
to vote as fully as if the undersigned were present in person, in the manner
indicated below. Receipt of the Notice of Meeting and the accompanying Proxy
Statement is hereby acknowledged.
THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED ON
THIS PROXY CARD. IF NO SPECIFICATION IS MADE, A VOTE FOR THE PROPOSAL WILL BE
ENTERED.
Should the undersigned be present and elect to vote in person at the Special
Meeting or at any adjournment thereof, upon notification to the Secretary of
Lifestream Technologies, Inc. at the Meeting of the Stockholder`s decision to
terminate the proxy, this power of attorney and proxy shall be deemed terminated
and of no further force and effect.
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS, WHICH
RECOMMENDS A VOTE FOR THE PROPOSALS. PLEASE REFER TO THE
PROXY STATEMENT FOR A DISCUSSION OF EACH OF THESE MATTERS.

1. Proposal to amend the Lifestream Technologies, Inc., Articles of
Incorporation to increase the number of authorized shares of Common Stock
from 250,000,000 shares to 750,000,000 shares.
[ ] FOR [ ] AGAINST [ ] ABSTAIN

The undersigned hereby revokes any and all prior proxies and acknowledges
receipt from the Company prior to the execution of this proxy of Notice of
Meeting, the Proxy Statement dated April 2, 2004.
Please sign exactly as your name appears. When signing as attorney, executor,
administrator, trustee, or guardian, please give your full name. If shares are
held jointly, each holder should sign. Please fill in the date the proxy is
signed.

Signature ______________ Signature if held jointly ______________ Dated ________
PLEASE COMPLETE, DATE, SIGN, AND MAIL THIS PROXY PROMPTLY IN THE ENCLOSED
SELF-ADDRESSED POSTAGE-PREPAID ENVELOPE.


Was ist Euere Meinung zu dem filing?

[Inkmarker]

Wer von Euch kann die Meldung vom 02.04.2004 mal durch ein Übersetzungsprogramm laufen lassen bzw. wo kann man ein solches legal kostenfrei herunterladen?

[Inkmarker]

Ich warte immer noch auf eine Antwort .

Der Handel heute morgen in Berlin ist sehr ruhig. Keine Kursveränderung zum Freitag.

[Saftladen]

ohne gewähr


INFORMATIONEN DES ZEITPLAN-14A ERFORDERT IM VOLLMACHTSFORMULAR INFORMATIONEN DES ZEITPLAN-14 VOLLMACHTSFORMULAR GEMÄSS ABSCHNITT 14(A) DES BÖRSENGESETZES VON 1934 Eingeordnet durch das registrant [ X ] eingeordnet durch Beteiligtes anders als das registrant [ _ ] Überprüfen Sie den passenden Kasten: [ ] einleitendes Vollmachtsformular [ ] vertraulich, denn Gebrauch von den Kommission nur (wie von Rule die Erlaubnis gehabt 14a-6(e)(2)) [ X ] endgültigen Vollmachtsformular-[ ] endgültigen zusätzlichen Materialien [ ] Material gemäß Richtlinie 14a-11(c) oder Richtlinie 14a-12 erbitten LIFESTREAM TECHNOLOGIEN, INC.. (Name von Registrant, wie in seiner Charter spezifiziert und des Person-Archivierung Vollmachtsformulars) Zahlung der Anmeldegebühr (überprüfen Sie den passenden Kasten): [ X ] Keine Gebühr erforderte [ ] die Gebühr, die unten auf Tabelle pro Austausch-Tat Richtlinien 14a-6(i)(1) und (1) Titel 0-11 jeder Kategorie Sicherheiten berechnet wurde, auf die Verhandlung zutrifft: (2) gesamte Zahl der Sicherheiten, auf die Verhandlungen zutrifft: (3) pro den Stückpreis oder anderen zugrundeliegenden Wert der Verhandlung berechnet gemäß Austausch-Tat Richtlinie 0-11: (4) vorgeschlagener maximaler gesamter Wert der Verhandlung: (5) kennzeichnen Gesamtgebühr gezahlter [ ] Überprüfung Kasten, wenn irgendein Teil der Gebühr versetzt wird, wie von Austausch-Tat Richtlinie 0 11(a)(2) zur Verfügung gestellt und die Archivierung, für die die versetzengebühr vorher gezahlt wurde. Kennzeichnen Sie die vorhergehende Archivierung durch Ausrichtung Aussage Zahl oder die Form oder Zeitplan und das Datum seiner Archivierung. (1) Zahlte Menge Vorher: (2) Form, Zeitplan oder Ausrichtung Aussage Nr.: (3) Einordnendes Beteiligtes: (4) Ordnete Datum Ein: LIFESTREAM TECHNOLOGIEN, INC.. 510 Clearwater Schleife, Suite 101, Pfosten-Fälle, Idaho 83854 NACHRICHT DER SONDERSITZUNG DER AKTIONÄRE, GEHALTEN ZU WERDEN APRIL 28, 2004 Zu unseren Aktionären: Sie werden herzlich eingeladen, sich eine Sondersitzung der Aktionäre (im folgenden, "die Sondersitzung") von Lifestream Technologies, Inc. (im folgenden, "die Firma"), eine Nevada Korporation zu sorgen, die am roten Löwe Templin`s, das Erholungsort bei 414 Osterster Allee fand, Pfosten-Fälle, Idaho, auf April 28, 2004, um 9:00 a.m., pazifischer Zeit oder an irgendwelchen und an allen Vertagungen davon gehalten wird. Der alleinige Zweck der Sondersitzung ist, eine Änderung (die "Änderung") zu Gründungsurkunde zu genehmigen, um die Zahl autorisierten Anteilen von Stammaktien von 250.000.000 Anteilen auf 750.000.000 Anteile zu erhöhen. Diese Sache wird völlig im Vollmachtsformular beraten über, das diese Nachricht begleitet. Wir glauben, daß die Zustimmung dieser Änderung angesichts des Company`s finanziellen Zustandes und die funktionsfähigen Notwendigkeiten und seine konsequente Notwendigkeit an den zusätzlichen autorisierten Anteilen mit dem Ziel das Erhalten der zusätzlichen Finanzierung zwingend ist. Die Direktion der Firma hat einmütig, daß der Änderungsvorschlag ratsam ist und in den besten Interessen der Firma festgestellt und empfiehlt, daß Sie FÜR die Änderung wählen. Das Brett hat den Geschäftsschluß an März 04, 2004, als der Stopptag für die Bestimmung jener Aktionäre, dessen zu Nachricht erlaubt wird, und zur Stimme an, die Sondersitzung geregelt. Die auf lagertransferregister sind nicht zwischen dem Stopptag und dem Datum der Sitzung geschlossen. Zustimmung des Änderungsvorschlags erfordert die bestätigende Stimme mindestens einer Majorität der nicht amortisierten Aktien von den Company`s Stammaktien, ob das Geschenk in der Person oder durch Vollmacht dargestellt. Dementsprechend ist es wichtig, daß Ihre Anteile bei der Sitzung dargestellt werden. PROMPT RETURN OF PROXIES WILL SAVE YOUR COMPANY DIE UNKOSTEN DER WEITEREN ANTRÄGE ZWECKS DIE NOTWENDIGE ZUSTIMMUNG ERREICHEN. OB ODER NICHT SIE, SICH DIE SITZUNG PLANEN SIE, BITTE KOMPLETT, DATUM ZU SORGEN UND DAS BEILIEGENDE VOLLMACHTSFORMULAR ZU UNTERZEICHNEN UND ES IM BEILIEGENDEN UMSCHLAG ZURÜCKZUBRINGEN. Ihre Vollmacht kann, im Schreiben, jederzeit vor der Zeit widerrufen werden, die es gewählt wird. Sie können Ihre Vollmacht auch widerrufen, indem Sie die Sitzung sich sorgen und in der Person wählen. Lesen Sie bitte die Vollmachtmaterialien sorgfältig. Ihre Stimme ist wichtig und die Firma schätzt Ihre Mitarbeit beim dem Betrachten und Fungieren auf den dargestellten Angelegenheiten. Sehr wirklich Ihr, /s/ Christopher Maus

[Inkmarker]

@ saftladen!

Besten Dank soweit.

Mit welchem Programm hast Du den Text übersetzt?

[Saftladen]

http://world.altavista.com

[Inkmarker]

# 11 Danke nochmal.

[Inkmarker]

Aktueller Kurs an der OTC: $ 0,046. Allerdings bis jetzt nur sehr geringe Umsätze. Vor Ostern will wohl keiner mehr rein.

Bin dabei mal die ganze Meldung vom 02.04.2004 in ein brauchbares Deutsch zu übersetzen.

Werde das Ergebnis dieses Experiments dann reinstellen.


Bis bald

Inkmarker.

[mounteverest]

Das ist die Ruhe vor dem Sturm

[connyco]

# 013
mit meinen dürftigen Englischkenntnissen verstehe ich diese Veröffentlichung so, daß Lifestream die zusätzlichen Mittel aus der Kapitalerhöhung brauchen, sonst wären sie pleite !
Sehe ich dies so richtig ???
Soll man jetzt darauf hoffen, daß eine Konsolidierung eintritt und die Papiere nochmals -,10 € oder höher sehen, oder das e v t l . sinkende Schiff verlassen.
Was meinen die Leidensgenossen ???????????

[Inkmarker]

@ connyco!

Nach bisherigen Erkenntnissen sollen die Aktien wohl für eine Wandelschuldverschreibung herausgegeben werden.

Bin immer noch mit der Meldung beschäftigt (bin derzeit zeitlich etwas eingeschränkt).

Allerdings sind Panikreaktionen momentan verfehlt, da die Herausgabe der Aktien scheinbar im Kurs eingepreist ist. Zudem kommen wohl die Aktien in absehbarer Zeit zumindest nicht komplett auf den Markt.


Grüße Inkmarker

[connyco]

# inkmarker
Danke vorerst --und frohe Ostern--

[Inkmarker]

Oh, oh...

kein guter Tag heute an der OTC:


LFTC: Volume Spike; 24% > 20-adsv, Stock -18.37%

MONDAY , APRIL 12, 2004 11:05 AM

This is the 1st VOLUME alert for LFTC in the past 7 calendar days.

Trading for Lifestream Technologies Inc (OTCBB: LFTC) has been heavier than usual in today`s session. By 11:05 ET, the stock had already traded 615,800 shares via 39 trades. The cumulative volume is 24.33% above its 20-day average of 495,281. Normally the stock experiences around 30 individual trades per session.

So far, today`s volume surge has caused a net decline in LFTC`s stock price. At the time of this alert, the stock was trading at $0.040, down $-0.009 (-18.37%).

One year ago, the Company`s shares closed at $0.110. The price has declined more than 63 percent since then.

Over the last 10 trading session LFTC has traded in a range between $0.045 and $0.055 and is currently trading 95.30% below its 52-week high of $0.851 set on November 24, 2003 and 11.11% below its 52-week low of $0.045 from April 08, 2004.

In the previous 3 sessions, LFTC trading has displayed a mixed trend. Closing results have been as follows:

April 08, 2004 --- closed at $0.049 up $0.003 (+6.52%) on 260,300 shares
April 07, 2004 --- closed at $0.046 down $0.001 (-2.13%) on 145,600 shares
April 06, 2004 --- closed at $0.047 down $0.002 (-4.08%) on 222,500 shares

The Company last released news on February 25, 2004:

"Lifestream Technologies Engages Rush Limbaugh to Promote Home Cholesterol Monitor"

LIFESTREAM TECHNOLOGIES INC
Lifestream Technologies, Inc. is a manufacturer of smart card-enabled healthcare diagnostic devices. The Company developed and currently markets a line of cholesterol monitors that provide test results in three minutes for at-home use by health conscious consumers and at-risk medical patients.


Kann man nur auf eine Kurserholung hoffen.

Grüße Inmarker

[marc22]

da bin ich aber froh, daß ich doch nicht wieder eingestiegen bin.

[Inkmarker]

Bin mit der Übersetzung wieder etwas vorangekommen.

Also es wurden Wandelschuldverschreibungen und Aktienoptionen über ca. $ 3 Millionen ausgegeben, die aber erst im Februar 2006 wandelbar sind.

Allerdings wurde September 2003 eine Wandelschuldverschreibung herausgegeben, die im Dezember bzw. Januar in Aktien umgetauscht wurde. In diesem Zusammenhang wurden ca. 62.000.000 an die Darlehensgläubiger ausgegeben.

Letztgenannte dürften auch für den anhaltenden Kursverfall verantwortlich sein.

[connyco]

Die OTC-Umsätze sind sehr rückläufig, sollten die Verkäufer langsam ihre Papiere los geworden sein ???!
Dies wäre uns ja zu wünschen, wenn wir irgendwann in absehbarer Zeit wieder Kurse von 0,06 - 0,08 € sehen wollen.
Der Handel in Berlin ist nicht mehr der Rede wert, heute 77 € !!!!
Mal abwarten, was nach dem 28.04. sich tut.

[Inkmarker]

Ich habe die Meldung mit dem "Babelfish" übersetzt und versucht ihr einen Sinn zu geben. Das Ergebnis seht Ihr unten. Die Übersetzung erfolgte nach besten Wissen. Eine Garantie für die Richtigkeit gebe ich aber nicht ab.


LIFESTREAM TECHNOLOGIEN, INC..

(Name von Registrant, wie in seiner Charter spezifiziert und des Person-Archivierung Vollmachtsfor-mulars)

- formelles -

Sehr geehrte Aktionäre:

Sie werden herzlich eingeladen, sich an der Sondersitzung der Aktionäre teilzunehmen („Spezialmee-ting“) von Lifestream Technologies, Inc. (im folgenden, " der Gesellschaft“). Sie findet in der „Nevada Korporation“, die am roten Löwe Templin`s Erholungsort gehalten wird, bei 414 Osterster Allee, Pfos-ten-Fälle, Idaho, auf April 28, 2004, um 9:00 a.m., pazifischer Zeit statt oder an weiteren Vertagungen. Der alleinige Zweck der Sondersitzung ist eine Änderung des genehmigten Kapitals, von derzeit 250.000.000 Aktien auf 750.000.000 Aktien.

Über den Zweck der Kapitalerhöhung werden Sie in dem beigefügten Formular informiert. Wir glau-ben, dass die Zustimmung zu dieser Änderung des Grundkapitals angesichts des finanziellen Zustan-des der Gesellschaft erforderlich ist. Durch die Erhöhung des Grundkapitals bezweckt die Gesellschaft eine zusätzliche Finanzierung zu erhalten. Die Direktion der Firma sind der Ansicht, dass der Ände-rungsvorschlag ratsam ist und im besten Interesse der Firma erfolgt und empfiehlt, daß Sie FÜR die Änderung stimmen.
Das Board hat den März 04, 2004, als den letzten Tag für die Bestimmung jener Aktionäre festgelegt, die auf dem „Spezialmeeting“ abstimmen können. Aktien, die nach dem 04. März erworben werden, sind nicht stimmberechtigt.

Für die Zustimmung des Änderungsvorschlags ist die Mehrheit der Stimmen der stimmberechtigten Aktien erforderlich, wobei auch eine Vertretung möglich ist. Dementsprechend ist es wichtig, dass Sie sich wenn Sie an der Sondersitzung teilnehmen schnellstmöglich zurückmelden.

Sie können eine erteilte Vollmacht jederzeit widerrufen... Lesen Sie bitte die Vollmachtmaterialien sorgfältig. Ihre Stimme ist wichtig und die Firma schätzt Ihre Mitarbeit beim dem Betrachtungen und Abstimmungen.


Mit freundlichen Grüßen Ihr Christopher Maus

Christopher Maus, Vorstandsvorsitzender der Pfosten-Fälle, Idaho April 2, 2004








FRAGEN UND ANTWORTEN ÜBER DIE VOLLMACHT-MATERIALIEN UND DIE SONDERSITZUNG


WARUM BERUFEN WIR DIESE SONDERSITZUNG EIN?

Um eine Änderung der Gründungsurkunde der Gesellschaft zugenehmigen. Die Anzahl der autorisier-ten Anteile sollen von 250.000.000 Stammaktien auf 750.000.000 Stammaktien erhöht werden.

WER IST BERECHTIGT AN DER ABSTIMMUNG TEILZUNEHMEN?

Alle Aktionäre die spätestens am 04. März Aktionäre der Firma waren. Folglich sind 154.675.276 Aktien stimmberechtigt.

WAS IST DER UNTERSCHIED ZWISCHEN EINEM STIMMBERECHTIGTEN AKTIONÄR UND EI-NEM "STREET NAME" AKTIONÄR?

Wenn Ihre Anteile direkt bei der Nevada Agency & Trust Company registriert sind, unsere Transfer-stelle, gelten Sie als stimmberechtigter Aktionär. Wenn Ihre Anteile bei einem Onlinebrocker oder von einer Bank oder einem anderen Kreditinstitut aufbewahrt werden, gelten diese als die materiellen Rechtsinhaber dieser Aktien, die von Ihnen gehalten gehalten werden, sogen. "Street Name" Aktionä-re.

WIE KANN ICH AN DER WAHL TEILNEHMEN?

Wenn Sie ein Aktionär stimmberechtigter Aktien sind, können Sie mit dem beiliegenden Formular ihre Stimme abgeben.
Falls sie „Street Name“ Aktionär sind, müssen sie ihrer Bank eine Anweisung für die Wahl erteilen.


KANN ICH MEINE STIMME AUCH PERSÖNLICH IN DER SITZUNG ABGEBEN?

Ja. Wenn Sie ein Aktionär stimmberechtigter Aktien sind, können Sie auch persönlich in der Sitzung Ihre Stimme abgeben. Wenn sie dagegen ein „Street Name“ Aktionär sind, können nur die Banken persönlich in der Sitzung die Stimme für sie abgeben.
WAS IST DIE EMPFEHLUNG DES VORSTANDES?

Der Vorstand empfiehlt für die Kapitalerhöhung zustimmen.

WARUM IST EINE ZUSTIMMUNG DER AKTIONÄRE ERFORDERLICH?

Nach dem Gesetz des Staates Nevada bedarf die Kapitalerhöhung der Zustimmung der Aktionäre.

HAT ES NACHTEILIGE FOLGEN FÜR DIE FIRMA, WENN DU KAPITALERHÖHUNG NICHT ZUSTANDEKOMMT?

Die Firma benötigt die Kapitalerhöhung

(a) für die vorhandenen Aktienoptionspläne
(b) zur Schuldentilgung
(c) zur Begleichung von Schuldscheinen
(d) zur Erfüllung von Wandelschuldverschreibungen
(e) um Aktien für unsere künftige Finanzierung herauszugeben.

Im Falle, dass die Kapitalerhöhung nicht genehmigt wird, können wir die vorgenannten Punkte nicht erfüllen, was zur Beendigung der Unternehmenstätigkeit führen könnte. Der Vorstand glaubt, dass die Kapitalerhöhung notwendig ist, um die anhaltend kritische Situation zu meistern und unsere Ge-schäfts- und Marketing-Strategien durchzuführen.

WAS PASSIERT, WENN ICH AUF DEM FORMULAR NICHTS ANKREUZE?

Wenn sie nichts ankreuzen, wird dies als Stimme für die Kapitalerhöhung gewertet.

KANN ICH MEINE STIMMABGABE BERICHTIGEN?


Ja. Sie können Ihre Vollmacht jederzeit widerrufen, indem sie von einer der drei folgenden Möglich-keiten Gebrauch machen:

- Schriftliche Mitteilung an unser Sekretariat im Falle der schriftlichen Stimmabgabe
- durch einreichen einer neueren Vollmacht im Falle einer Bevollmächtigung
- indem sie an der Sitzung persönlich teilnehmen


WIRD DIE ZUSTIMMUNG DURCH DIE AKTIONÄRE BEREITS GESICHERT?

Der Vorstand besitzt 5,53% der stimmberechtigten Aktien. Es gibt bisher keine Vereinbarung mit an-deren Aktionären, die die Zustimmung versichert haben.

GIBT ES WEITERE ANGELEGENHEITEN, DIE AUF DER SITZUNG BESPROCHEN WERDEN?

Nein, auf der Tagesordnung steht kein weiterer Punkt an.

ANGABEN ZUM AKTIENBESITZ DES VORSTANDES.

- wird nicht näher ausgeführt, Angaben sind mehr organisatorischer Art -

----------------------------------------------------------------------------------------------------------------------------------------


(1) - organisatorische Angaben -

(2) - organisatorische Angaben -


(3) Die angegebenen Prozentsätze (bezieht sich auf die vorstehenden Angaben zum Aktienbesitz der Vorstandsmitglieder) basieren auf dem Stand vom 04.03.2004. Zu diesem Zeitpunkt waren 154.675.276 Aktien ausgegeben.

... Es folgen weitere Einzelheiten zu den Aktien und Aktienoptionen der Vorstandsmitglieder in den Punkten (4) – (11)

(12) RAB Europa Kapital Ltd. besaß am 04.03.2004 Wandelschuldverschreibungen die in 40.200.000 Aktien umgewandelt werden können. Die RAB Europa Kapital Ltd. hat das Recht nicht aber die Pflicht die Forderungen in Aktien umzuwandeln. Würde die RAB Europa Kapital Ltd. von ihrem Recht Gebrauch machen, so wären die angegebenen 9,99% überschritten.

(13) Angaben dazu, dass Wandelschuldverschreibungen einbezogen sind


ANTRAG 1

ZUSTIMMUNG ZUR KAPITALERHÖHUNG

Der Vorstand hat einstimmig die Einberufung der Aktionärsversammlung Kapitalerhöhung beschlos-sen und vorgeschlagen die Anzahl des genehmigten Kapitals von 250.000.000 Aktien auf 750.000.000 Aktien zu erhöhen. Die Erhöhung des Grundkapitals würde nicht die Zahl der Vorzugsak-tien beeinflussen, die bei 15.000.000 Aktien liegt und von denen keine herausgegeben worden ist. Am 04.03.2004 waren 154.675.276 Aktien ausgegeben.
Der Vorstand glaubt, dass es zwingend erforderlich ist, das genehmigte Kapital zu erhöhen, um genü-gend Aktien zur Verfügung stellen zu können und so die Ausübung der Wandelanleihen zu ermögli-chen. Der Vorstand glaubt, dass die Kapitalerhöhung für die finanzielle Zukunft der Gesellschaft erfor-derlich ist, und empfiehlt der Änderung zuzustimmen. Mit der Zustimmung der Aktionäre wird die Kapi-talerhöhung wirksam.

HINTERGRUNDINFORMATIONEN

Am 30. Juni 2003 hatten wir 92.894.590 stimmberechtigte Aktien ausgegeben, und 7.105.410 nicht-ausgegebene Aktien, die für die Ausgabe vorgesehen waren. Im August 2003 wandelte ein Anleihe-gläubiger die Darlehensforderung in Höhe von $ 700.000 in Aktien um, so dass uns noch 105.410 Aktien übrig blieben. Wie in unserem Bericht zum Jahresabschluss 2003 am 30. Juni erwähnt, sind wir auf Grund des negativen Betriebsergebnisses und des negativen cashflow aus der Geschäftstätigkeit seit der Gründung der Firma in verstärktem Maße von einer alternativen Finanzierung abhängig.
Am 15. September 2003 genehmigte der Vorstand den Verkauf und die Austeilung einer 8 %igen Wandelschuldverschreibung in Höhe von $ 3.350.000, wandelbar im September 2006. Die Schuld-scheine sind in 25.769.231 Aktien zu einem Kurs von $ 0,13 je Aktie wandelbar, und enthalten das Recht zusätzliche 12.884.615 Aktien zu erwerben. In Übereinstimmung mit dieser Vereinbarung ge-nehmigten unsere Aktionäre im Dezember 2003 eine Kapitalerhöhung auf 250.000.000 Aktien.
Wegen der anhaltenden Abnahme des Aktienkurses und unserem Wunsch Investoren zu veranlassen, ihre Schuldscheine umzuwandeln, schloss die Gesellschaft am 13. Januar 2004 mit den Gläubigern einen Vertrag über die Wandelschuldverschreibung, die im September ausgegeben wurde. Darin stimmte jeder Anleihegläubiger unter Verzicht seiner Rechte zu, seine Schuldscheine gegen Aktien der Gesellschaft zu einem Kurs von $ 0,09 pro Schuldschein in Aktien auszutauschen.
Dementsprechend gab die Gesellschaft im Januar 2004 34.655.011 Aktien im Wert von $ 2.975.624 heraus. Im Dezember 2003 wandelten drei Anleihegläubiger Darlehen im Wert von $ 1.279.241 in 12.378.778 Aktien um und im Februar 2004 übten zwei Investoren ihre Rechte zum Erwerb von 4.615.384 Aktien aus.
Auf Grund der oben beschriebenen Finanzierungen gaben wir in der Zeit von August 2003 bis Februar 2004 ungfähr 62.000.000 Aktien heraus, woraus sich die Anzahl der ausgegebenen Aktien von 154.675.276 am 4. März 2003 ergibt.




NEUE FINANZIERUNGEN

Am 19. Februar 2004 kam es zum Abschluss einer Wandelschuldverschreibung in Höhe von $ 2.775.000 mit der Option zum Erwerb weiterer Aktien. Im Falle, dass die Schuldschein zu dem ange-gebenen Konvertierungskurs von $ 0,05 pro Anteil umgetauscht werden, würden ungefähr 55.500.000 Stammaktien ausgegeben. Im Falle, dass von der Kaufoption zu $ 0,065 pro Anteilschein Gebrauch gemacht wird, würden weitere 16.650.000 Aktien ausgegeben werden. Der Umwandlungskurs ist ab-hängig von verschiedenen Faktoren. Außerdem benötigen wir 125% der Anteile in Aktien, die nach der Umwandlung und der Ausübung der Option ausgabefähig sind. Dies zwingt die Gesellschaft dazu, eine Reserve von 90.187.500 Aktien für den Fall der Umwandlung und der Ausübung der Option zu registrieren.
In diesem Zusammenhang entschloss sich die Gesellschaft die Aktionärsversammlung um Zustim-mung zu ersuchen, eine Kapitalerhöhung im Rahmen von 500.000.000 Aktien durchzuführen.
Falls die Zustimmung der Aktionärsversammlung erreicht wird, sind die Investoren bereit weitere $ 1,22 Wandelschuldverschreibungen zu den Konditionen zu übernehmen, die schon am 19. Februar 2004 ausgehandelt worden.
Wenn diese Schuldscheine verkauft benötigen wir weitere 42.864.865 Aktien.
Im März 2004 gaben wir eine zusätzliche Wandelschuldverschreibung über $ 122.000 heraus. Zudem gaben wir 732.000 Aktienoptionsscheine im Zusammenhang mit dieser Vereinbarung heraus. Die Wandelschuldverschreibung und Aktienoption wurden zu denselben Bedingungen geschlossen, wie am 19. Februar und können in 3.172.000 Aktien umgewandelt werden.


ZUSAMMENFASSUNG ÜBER DIE MÖGLICHE AUSGABE VON AKTIEN

Am 4. März 2004 hatten wir 154.675.276 stimmberechtigte Aktien Aktien ausgegeben, und könnten erforderlichen Falls weitere 197.020.560 Aktien ausgeben. Dies ergibt sich aus folgendem

- Zusammenfassung der letzten Punkte (wird nicht näher ausgeführt)

Wir sind derzeit nicht in der Lage die ausgegebenen Wandelschuldverschreibungen, die beginnend im Februar 2006 fällig werden zurückzuerstatten. Das derzeit vorhandene „Aktienkapitial“ ermöglicht nur eine teilweise Umwandlung der Wandelanleihe. Wenn wir die Kapitalerhöhung nicht wie geplant durchführen und wir nicht genügend Bargeld auftreiben können, sind wir nicht in der Lage die Schul-den zurückzubezahlen und setzen Schadenersatzansprüchen aus. Des Weiteren sind wir auch nicht in der Lage weitere Finanzierungsvereinbarungen zu treffen, und die am 19.04.2004 vereinbarten Wandelschuldverschreibungen in Höhe $ 1,22 Millionen herauszugeben. Außerdem gibt es dann kei-ne die Firma weiter am Laufen zu halten.



ANFORDERUNG FÜR ZUSÄTZLICHE AUTORISIERTE ANTEILE

Obgleich die Kapitalerhöhung notwendig ist, um der Gesellschaft Kapital zur Verfügung zu stellen, gehen unsere Bestrebungen dahin, weiteres zusätzliches Kapital auf anderem Wege zu beschaffen, die Ausgaben zu verringern und durch unsere Geschäfte einen positiven Bargeldumlauf (cash flow) herbeizuführen. Weiterhin sind wir bemüht die Produktion unseres Produktes durch zusätzliche Mar-keting-Bemühungen zu erhöhen.
Die Kapitalerhöhungen sind erforderlich, weil derzeit nicht die Möglichkeit besteht, Geld auf andere Weise aufzutreiben. Wir benötigen aber dieser Geld um unseren Warenbestand finanzieren zu kön-nen, sowie die Marketing-Kampagnen, die im Oktober 2003 anfingen zu finanzieren.
Ohne die Kapitalerhöhungen wären wir wahrscheinlich gezwungen unsere Geschäftstätigkeit zu be-schränken oder vielleicht sogar aufzuhören.
Auch wenn wir die Zustimmung der Aktionäre zu der Kapitalerhöhung erhalten, kann nicht versichert werden, dass wir zusätzliches Kapital aufbringen können. Wir glauben allerdings, dass wir durch die Kapitalerhöhung unsere Bilanzen aufbessern können und wir in einer bessere Position sind um neue Finanzierungen durchführen zu können.
Verbesserung zu unseren Finanzberichten und zu Position, die die neuen Finanzierungen vorausset-zen, glauben wir, daß wir in einer Position sind, zum der zusätzlichen Finanzierung zu erhalten, die notwendig ist fortzufahren, unseren Unternehmensplan einzuführen. Durch den auf Grund der Kapi-talerhöhung erzielten Vorrat an Aktien besteht auch die Möglichkeit mit anderen Firmen zusammenar-beiten zu können und das Geschäftsfeld der Gesellschaft zu erweitern. Die Gesellschaft hat allerdings insoweit noch keine konkreten Vorstellungen.

AUSWIRKUNGEN DER KAPITALERHÖHUNG AUF DIE AKTIONÄRE

Die durch die Kapitalerhöhung hervorgebrachten Aktien haben die selben Rechte, wie die bisherigen auf dem Markt befindlichen Aktien. Die durch die Kapitalerhöhung hervorgebrachten Aktien beeinflus-sen die Aktionäre in der Weise, dass eine Verwässerung eintritt. Die Kapitalerhöhung hat weiter zur Folge, dass der zukünftige Gewinn je Aktie sowie eine etwaige Dividende geringer ausfallen werden, wenn die Gesellschaft rentabel wird. Weiterhin könnte durch die Kapitalerhöhung und einer damit verbundenen Ausgabe von Aktien der Börsenkurs sinken, falls ein Überhang auf dem Markt entsteht. Eine Austeilung von Aktien aus dem genehmigten Kapital muss der OTC-BB gemeldet werden, bedarf aber keiner Zustimmung der Aktionäre und zwar auch denn nicht, wenn die Ausgabe unter dem aktu-ellen Marktwert erfolgt. Etwas anderes gilt nach dem Recht des Staates Nevada nur dann, wenn die Ausgabe zum Zwecke einer Fusion erfolgt. Aktien können folglich zum Zwecke der Finanzierung auch ohne vorherige Mitteilung ausgegeben werden. Die Aktionäre der Gesellschaft haben kein Vorkaufs-recht bezüglich der zusätzlich ausgegebenen Aktien.

KEINE KAPITALERHÖHUNG ZUM ZWECKE DER ABWEHR EINER ÜBERNAHME

Die Kapitalaufnahme durch die Gesellschaft erfolgt nicht um eine Übernahme abzuwehren. Die Kapi-talerhöhung hat nicht die Bemühungen eines Beteiligten zum Ziel die Steuerung der Gesellschaft zu übernehmen. Allerdings könnten die neuen Aktien dazu verwendet werden es dem Vorstand zu er-möglichen eine Übernahme abzuwehren, indem er Aktien zu diesem ausgibt. Es gibt derzeit aber keine Pläne eine Übernahme zu verhindern. Dem Vorstand sind zur Zeit keine Übernahmebemühun-gen von anderen Personen bekannt. Der Vorstand will durch die Kapitalerhöhung auch keine Über-nahmeangebote verhindern.

EMPFEHLUNG DES VORSTANDES

- nochmalige Empfehlung, den Vorschlag anzunehmen -

interessant: ... Wir haben derzeit eine negative Arbeitkapitalposition, die hauptsächlich auf unserer Unfähigkeit beruht, der anhaltenden Nachfrage nach unserem Produkt eine ausreichende Menge ge-genüberzustellen auf Grund unserer finanziellen Schwierigkeiten.

... obwohl die Austeilung der Aktien zu einer Verwässerung führt, können wir dadurch unsere kurzfris-tigen und langfristigen Unternehmensziele erreichen und hoffnungsvoll in die Zukunft schauen.

Die Stimmenthaltung und Nein-Stimmen führen zu einer Stimme gegen die Änderung.

- Der Rest betrifft nur den organisatorischen Teil -


Einiges macht Angst, anderes gibt Hoffnung.

Grüße Inkmarker

[Inkmarker]

Heute mal endlich wieder im plus!

Last Sale: 0.04 +0.005 +14.29%

Volume: 1,166,474 Previous Close: 0.035 (4/15/2004)
03:54:57 PM 4/16/2004


Today`s High: 0.045
Today`s Low: 0.035

Best Bid: 0.035
Best Ask: 0.045

Grüße Inkmarker

[connyco]

# 22/23 Inkmarker
Es macht Hoffnung, wenn die Lifestream die Nachfrage nach den Testgeräten nicht befriedigen kann, weil liquide Mittel fehlen. Das heisst doch, daß der Tester am Markt ankommt. Somit müssten doch Produktion aufrechterhalten werden um den Absatz und damit verbunden Rentabilität und Gewinn zu stabilisieren. So würde man es jedenfalls in Old Germany handhaben.
Hoffen wir daß die Yankee`s auch so denken und der 28. April für uns positiv endet !!!

[Inkmarker]

@ connyco!

Ich sehe es grundsätzlich genauso.

Das Problem ist nur, dass das genehmigte Kapital auf 750.000.000 Aktien erhöht wird. D.h. LFTC kann theor. aus der Kapitalerhöhung so viel Aktien, wie sie wollen, ausgeben, ohne dass hierfür irgendeine Genehmigung erforderlich wäre. Dagegen spricht allerdings, dass der Vorstand auch noch eine Menge Aktien hält, die dann nichts mehr wert wären. Auf der anderen Seite könnten die Herrn so ihre Gehälter sichern.

Entscheidend wird m.E. sein, ob es für die angebotenen Geräte tatsächlich einen Markt gibt. Sollte dies der Fall sein, was sich spätestens beim nächsten Jahresabschluss zeigt, wird LFTC auch wieder von den Banken Kredit bekommen. Dann sollten wirklich wieder höhere Kurse drin sein.

Im Augenblick stehen die Chancen m.E. 50/50.

Ich denke außerdem, dass die Kapitalerhöhung ohne Probleme durchgehen wird.

Grüße Inkmarker

[connyco]

10 % plus im Amiland, Licht am Ende des Tunnels - der 28.0.4. rückt näher !! ?

[Inkmarker]

Es ging zwar die Woche wieder auf und ab, im Ergebnis bleibt aber festzuhalten, dass sich der Kurs von seinen Tiefstständen gelöst hat.

Schlusskurs vom Freitag an der OTC:


Last Sale: 0.043 +0.003 +7.50%

Volume: 709,103 Previous Close: 0.04 (4/22/2004)
02:57:53 PM 4/23/2004


Today`s High: 0.045
Today`s Low: 0.035

Best Bid: 0.042 Best Ask: 0.045
Bid Size: 5000 Ask Size: 5000

Auf eine hoffentlich gute nächste Woche. Am Mittwoch findet auch die Hauptversammlung statt. Dann dürfte auch wieder mehr Sicherheit in die Aktie einkehren.

Grüße Inkmarker

[mounteverest]

Wenn die 0,045$ im Bid auftauchen, dann geht sie Post ab

[Inkmarker]

Und auch heute wieder im plus. Der Kurssturz vom Ostermontag ist jetzt wieder ausgeglichen.

Last Sale: 0.05 +0.007 +16.28%

Volume: 1,727,337 Previous Close: 0.043 (4/23/2004)
04:00:06 PM 4/26/2004


Today`s High: 0.05
Today`s Low: 0.042

Best Bid: 0.047 Best Ask: 0.05
Bid Size: 5000 Ask Size: 5000

Mal schauen, ob wir den Kurs morgen halten, oder ob im Vorfeld der Hauptversammlung am Mittwoch wieder verkauft wird.

Grüße Inkmarker

[connyco]

Heute auf Höchstkurs 0,050 geschlossen in USA !
Offensichtlich geht man von positiven Beschlüssen am 28. aus.
Weiß evtl. hier schon jemand mehr ???

[Inkmarker]

# 30!

Meines Wissens soll nur über die Kapitalerhöhung abgestimmt werden.

Ich denke, dass diese inzwischen wohl eingepreist ist, denn an der Annahme bestehen nach der Mitteilung oben wohl keine Zweifel.

Denke mal, dass die Unsicherheit nach der Abstimmung erstmal raus ist. Sollten dann noch positive Mitteilungen über die Vermarktung kommen, sollten auch in absehbarer Zeit zumindest wieder $ 0,10 drin sein (hoffe dies zumindest).

Also: Abwarten und Tee trinken.


Grüße Inkmarker

[Inkmarker]

Nochmal ich!

Nach meinen Beobachtungen scheint derzeit schon Interesse an der Aktie zu bestehen. Denke mal die Umsätze sind für einen OTC-Wert o.k.. Solange keine Stücke in hoher Millionenzahl geworfen werden (vgl. Ostermontag), steigt der Kurs.

Bleibt zu hoffen, dass die noch übrigen Aktien in kursschonender Art und Weise an den Mann (oder Frau) gebracht werden.

[mounteverest]

Die Zeichen stehen auf BUY

http://www.americanbulls.net/StockPage.asp?CompanyTicker=LFT…

[Inkmarker]

So heute ist es soweit:

Die Hauptversammlung findet statt, bei der über die Kapitalerhöhung abgestimmt wird.

Wer erste Nachrichten hat, bitte gleich reinstellen!

Der Kurs konnte sich an der OTC ja im späten Handel noch ein wenig erholen. Mal schauen was heute passiert.

Grüße vom Inkmarker, der gespannt wartet.

[connyco]

Hat jemand schon Info`s darüber, was gestern sich ergeben hat ????

[connyco]

######
Hallo, hallo, hallo, haben sich alle hier vom Board abgemeldet

[Inkmarker]

# 36

Natürlich nicht. Ich habe auch schon mal nach Neuigkeiten gesucht, aber bisher leider noch nichts gefunden.

Die einzige "Neuigkeit" ist der leider wieder fallende Kurs .

Grüße Inkmarker

[mounteverest]

Das sieht sehr gut aus Der Weg Richtung 0,10 $ wird sichtbar

[Inkmarker]

#38

Wäre ja schön.

Werden die Stimmen übrigens noch gezählt?

[mounteverest]

Ich glaube, dass die dagegen gestimmt haben und das Management von Lifestream jetzt einen anderen Weg sucht (darum die Verzögerung ohne Info), sonst wäre der Kurs nicht so hoch

[mounteverest]

WOW !!!

+700 %

[connyco]

# 41
Dieser Kurs ist garantiert ein "Tappfuhler" und soll wohl 0,020 € heissen !!!
Aber trotzdem sieht es gut aus

[Inkmarker]

Die Schere zwischen bid ($ 0,033) und ask ($0,044) wird größer.

Ist mir allerdings nicht ganz klar warum, wenn solche Mengen von Aktien auf dem Markt sind.

Immer noch keine neuen Meldungen von der Abstimmung. (?)

Grüße Inkmarker

[connyco]

In den letzten Tagen in USA fast nur Käufe, wenn auch in kleineren Posten 20-30Tausend.
Ob man dort vor Ort mehr weiß ??

[mounteverest]

Die Zeichen stehen wieder auf BUY

http://www.americanbulls.com/StockPage.asp?CompanyTicker=LFT…

[mounteverest]

Der 10QSB ist da:

http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fred…

[connyco]

dies bedeutet sicher nichts Gutes ??

[mounteverest]

Keine Panik So schlimm sieht es nicht aus. Vor 2005 werden wir die 0,10$ meiner Einschätzung nach aber nicht sehen

[Inkmarker]

Neue Veröffentlichung (allerdings nicht wirklich interessant):

Lifestream Technologies Names TheSUBWAY.Com as Its New Financial Public Relations Firm

2004-05-25 06:30 ET - News Release

POST FALLS, Idaho -- (Business Wire) -- May 25, 2004

Lifestream Technologies, Inc. (OTCBB:LFTC), a leading
developer and marketer of consumer cholesterol monitors and
professional screening instruments, announced today that it has named
TheSUBWAY.com as its new financial public relations firm.
"This is a significant step for our Company and our stockholders
as the need to communicate future developments with the public
marketplace is expected to increase," commented Christopher Maus,
Lifestream`s President and CEO. "Until now, we have been operating
without a financial public relations firm due to the related cost. To
better utilize our resources, we waited until we thought such services
would be most effective. Earlier this year, we started our selection
process, attempting to identify and retain the right firm to
communicate our messages. It is with great pleasure that we announce
the selection of TheSUBWAY.com to support the Company`s communication
needs with the investment community."
TheSUBWAY.com, a full-service public relations firm specializing
in small-cap and OTC growth stocks, was founded by President and CEO
Charles T. Tamburello. After spending over eleven years in the
financial sector, Mr. Tamburello now works in financial public
relations, promoting undervalued or virtually undiscovered companies.
"We are very impressed with the performance of TheSUBWAY.com`s
current and past clients," noted Maus. "They have been effective in
getting their clients noticed within the investment community. Our
goal is to see the Company`s value fully realized in the market place.
In our assessment, TheSUBWAY.com can help create a more desirable
market for Lifestream stockholders."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol
monitors to consumers and healthcare professionals that provide test
results in three minutes.
The Company`s product line aids the health conscious consumer in
monitoring their risk of heart disease. By regularly testing
cholesterol at home, individuals can monitor the benefits of their
diet, exercise and/or drug therapy programs. Monitoring these benefits
can support the physician and the individual`s efforts to improve
compliance. Lifestream`s products also integrate a smart card reader
further supporting compliance by storing test results on an
individual`s personal health card for future retrieval, trend analysis
and assessment.
The Lifestream Cholesterol Monitor is an affordable, hand-held
device, which provides users with accurate results in less than three
minutes. The product line has been designed to accommodate The Data
Concern(TM) smart card allowing multiple users the ability to store
their personal results. Lifestream`s products are now available in
pharmacy and retail outlets nationwide. To find retailers that carry
Lifestream`s products, go to "Store Locator" on www.knowitforlife.com
or contact Customer Care at 888-954-LIFE. For Company information,
visit www.lifestreamtech.com.

This news release includes certain forward-looking statements
within the meaning of the safe harbor protections of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements regarding our
current business plans, strategies and objectives that involve risks
and uncertainties, and in particular statements referring to our
expectations for increased market penetration and improved gross
margins from our recently introduced second generation consumer
monitors and statements regarding our expectations that we can obtain
necessary additional financing and investment. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ from anticipated results. The forward-looking
statements are based on our current expectations and what we believe
are reasonable assumptions given our knowledge of the relevant
markets; however, our actual performance, results and achievements
could differ materially from those expressed in, or implied by, these
forward-looking statements. Factors, within and beyond our control,
that could cause or contribute to such differences include, among
others, the following: the success of our capital-raising and
cost-cutting efforts, developing and marketing relatively new medical
diagnostic devices, including technological advancements and
innovations; consumer receptivity and preferences; availability,
affordability and coverage terms of private and public medical
insurance; political and regulatory environments and general economic
and business conditions; the effects of our competition; the success
of our operating, marketing and growth initiatives; development and
operating costs; the amount and effectiveness of our advertising and
promotional efforts; brand awareness; the existence of adverse
publicity; changes in business strategies or development plans;
quality and experience of our management; availability, terms and
deployment of capital; labor and employee benefit costs; as well as
those factors discussed in our most recent Registration Statement on
Form SB-2 filed April 5, 2004, and in "Item 1 - Our Business," "Item 6
- Our Management`s Discussion and Analysis," particularly the
discussion under "Risk Factors - Substantial Doubt as to our Ability
to Continue as a Going Concern" and elsewhere in our most recent
Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003,
both filed with the United States Securities and Exchange Commission.
Readers are urged to carefully review and consider the various
disclosures made by us in this report, in the aforementioned Form SB-2
and Form 10-KSB, and those detailed from time to time in our other
reports and filings with the United States Securities and Exchange
Commission that attempt to advise interested parties of the risks and
factors that are likely to affect our business.
Contacts:

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)

[micha12]

Heute 50% an OTC BB

news von heute (Übersetzung)

WESTON, Fl, Mag. 26, 2004 (MARKT-LEITUNG über COMTEX) -- TheSUBWAY.com nennt die folgenden Aktien zu seiner auf lagerfokus-Liste: Lifestream Technologies Inc. (OTC BB: LFTC), CVS Corporation (NYSE: CVS), ADC
Nachrichtentechniken (Nasdaq: ADCT), Intel Corporation (Nasdaq: INTC). Lifestream Technologies, Inc. (OTC BB: LFTC), ein führender Entwickler und ein Marketingspezialist der Verbrauchercholesterinmonitoren und der professionellen Siebunginstrumente, verkündet, daß CVS Corporation (NYSE: CVS), eine der nation`s führenden Droge-Speicherketten mit über 4.100 Speichern, hat angefangen, einen Kupon mit $15 Diskonten in Richtung zum Erwerb Lifestream`s des Hauptcholesterin-Monitors auf jeder neuen Verordnung für ein Cholesterin anzubringen, das Droge senkt. Die entwickelte Firma und vermarktet z.Z. eine Linie der Cholesterinmonitoren zu den Verbrauchern und die healthcare Fachleute, die Testergebnisse in drei Minuten zur Verfügung stellen.

[connyco]

GEstern 50% + im Amiland, leider kann ich heute Morgen nicht mehr die Kursentwicklung sehen. Ich bin mal gespannt, wie es heute bei uns aussehen wird.
(Gestern habe ich noch bei mir gedacht, evtl. noch 100.000 Stück nachzukaufen, um meinen Einstieg zu reduzieren, hab`s aber dann nicht getan, weil wir mit Besuch zusammensaßen und gequatscht haben Sch.....!!)

[mounteverest]

Die Zeichen stehen erneut auf BUY! http://www.americanbulls.com/StockPage.asp?CompanyTicker=LFT…

[Inkmarker]

... announced today that CVS Corporation (NYSE:CVS), one of the nation`s leading drug store chains with over 4,100 stores, has started attaching a $15 discount coupon toward the purchase of Lifestream`s Home Cholesterol Monitor on every new prescription for a cholesterol lowering drug.

Na das klingt ja richtig gut. Kann man nur hoffen, dass LFTC mal endlich was mit ihren Monitoren verdient.

Positiv ist auch das die Umsätze mit ca. 1 Mill. gehandelter Aktien nicht so hoch lagen, also keine Aktien auf den Markt geschmissen worden.

Sollte sich der Verkauf der Monitore positiv entwickeln, so ist auch die derzeitige Marktkapitalisierung von $ 6,75 (oder $ 7,26) Millionen nicht sehr hoch.

Grüße Inkmarker

[Inkmarker]

Die Vermarktung wird weiter fortgesetzt:

Neil Luckianow to Head National Sales Team; Lifestream Technologies Acquires Extensive Sales & Marketing Experience with Former Amira and LifeScan Executive
POST FALLS, Idaho

Lifestream Technologies, Inc.
Investor Relations Contact:
Gerri Vance, 208-457-9409 ext. 1221
[e-mail]
Lifestream Technologies, Inc. (OTCBB:LFTC), a leading developer and marketer of consumer cholesterol monitors and professional screening instruments, announced today that Neil Luckianow has been retained to manage and direct its national sales force. Mr. Luckianow, a principal in NCL & Associates, LLC, brings an extensive background in sales and marketing from the glucose home diagnostic business.

Previously with Amira Medical/Mercury Diagnostics (Roche Diagnostics, Inc.) as Director of Sales, Mr. Luckianow was responsible for the creation and implementation of a health care professional call strategy. He also designed a product distribution strategy for the company`s glucose monitoring product from first product entry until Roche Diagnostics acquired Amira. As Senior Director, National Sales, for Magic American Corporation, Mr. Luckianow developed strategic and tactical plans for a new line of home health care products and successfully launched the new product line into 6,000 plus retail outlets. Prior to Magic American, Mr. Luckianow held various sales and trade development positions with LifeScan, Inc., a Johnson and Johnson company, where he was responsible for retail sales, promotions and distribution channels for the company`s glucose monitoring products.

"We are extremely pleased to be able to add Neil`s experience to head our sales representative team," said Christopher Maus, Lifestream`s President and Chief Executive Officer. "His extensive background in sales, marketing and general management for the consumer diagnostic markets can provide invaluable expertise to Lifestream as we continue to engage our marketing campaign and expand our presence on the retail shelf."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

[Nerverl]

Warum is es denn so ruhig geworden hier? Jetzt gehts doch erst richtig los!!!

[Inkmarker]

Der Kurs wird m.E. erst richtig anspringen, wenn sich die Vermarktung der Monitore auch in einem positiven Cashflow niedergeschlagen hat, was wohl erst im III. Quartal der Fall seien dürfte.

Bis dahin heißt es abwarten und ein paar Stücke zu kaufen!

[Nerverl]

@Inmaker

Ich denke das ev. spekulationen im Vorfeld bereits den Kurs in die Höhe treiben könnten? Ist doch bei dieser Marktkapitalisierung nicht so abwegeig, oder?

[Inkmarker]

# 57

Auf das "k" in meinem Namen muss ich schon bestehen!

Ansonsten hast Du natürlich recht, dass schon im Vorfeld Spekulationen den Kurs anheizen könnten.

Ich glaube aber, dass die letzten News leider schon eingepreist sind. Die Aktie stieg damals unter relativ hohen Umsätzen. Jetzt sind die ersten Zocker wieder ausgestiegen und der Kurs entsprechend zurück gekommen.

Momentan ist zumindest eine Stabilisierung bei so um die $ 0,03 eingetreten. Mein Kursziel liegt derzeit allerdings bei $ 0,09 (allerdings auf Basis von 6 Monaten).

Na ja, mal abwarten.

Grüße Inkmarker

[ustrading]

Das Management reagiert auf die Kursverluste der letzten Tage. Allerdings ist so ein Statement auch ein Eingeständis dafür, das das Business nicht so läuft, wie man sich das erwartet hat


Dear Fellow Shareholders:

I share everyone`s disappointment in the recent share price decline. The Company has received a large number of emails and calls regarding this situation and it has been a challenge to return all the calls in a timely manner. Therefore, this communication is intended to address and assuage the concerns expressed in emails and over the phone.

The recent share price decline cannot be simply tied to any recent change in the Company`s day-to-day operations since many consider the recent changes to be beneficial in nature. The Company is continuing operations according to its business strategy. With the addition of Walgreen`s and the continuation of our awareness programs, we do not anticipate moving away from this strategy. We see nothing that accounts for the recent decline in market capitalization. In fact, operationally, the Company is in better shape today than 18 months ago.

We can only speculate as to any possible external cause for the share price decline. Lifestream recently became aware of the unauthorized listing on the Berlin-Bremen Stock Exchange. Many allegations have recently been discussed in the press regarding a possible arbitrage on U.S. markets leveraging stock that might not exist on the Berlin-Bremen Stock Exchange (BBSE). While these allegations have not been verified, the Company believes the potential downside of the exchange listing could be greater than any benefits being derived. As a result, the Company has sent written demand to the Berlin-Bremen Stock Exchange that it immediately cease trading in the Company`s common stock and take whatever measures are necessary to completely delist the Company`s common stock from the BBSE.

Our primary strategy to address the current share price decline is to stay on course and operationally grow the Company, building on the fundamentals of revenue growth and profitability. We are confident that, in time, our ongoing operational performance will overcome any external forces negatively impacting the Company`s price per share.

Thank you for your ongoing support.

[Inkmarker]

@ all!

Also wenn ich die letzte Meldung richtig verstanden habe, plant LFTC ein Delisting in Berlin. Ist natürlich nicht so schön für uns, wenn der letzte deutsche Handelsplatz geschlossen wird.

A B E R , K E I N E P A N I K !!!

Die in D`land gekauften Aktien können wieder direkt in den Staaten verkauft werden. Ich habe gerademal mit Consors telefoniert, wo mir dies auf Nachfrage bzgl. LFTC-Aktien mitgeteilt wurde. Bei Consors muss man einfach den Handelsplatz USA einstellen und die Zuordnung zur OTC erfolgt dann automatisch.

Grüße Inkmarker

[Inkmarker]

N E W S :

Lifestream Technologies` Shipments Double in Fourth Quarter 2004; With additional distribution and increasing awareness, Lifestream sees its business expanding in 2005

2004-07-07 06:30 ET - News Release

POST FALLS, Idaho -- (Business Wire) -- July 7, 2004

Lifestream Technologies(TM) (OTCBB:LFTC), the leading
manufacturer of home cholesterol monitors and professional screening
devices, today announced that shipments in the fourth quarter were
twice that of the same quarter ending 2003. The addition of a new
retail account contributed to this increase in shipments.
"With the addition of a major retailer and our recent advertising
and promotional programs, we are looking forward to an improvement in
sales numbers," said Christopher Maus, Lifestream President and CEO.
"An important component of improving our cash position is better
management of our inventory as our sales increase. We expect to see an
improvement in performance over the coming quarters with continued
strong orders, increased margins, and cost containment. We continue to
aggressively pursue the remaining distribution channels through the
addition of new retail accounts."
"Lifestream`s revenue recognition policy does not necessarily
result in revenue recognition at the time product is shipped and,
therefore, shipments may not be an indicator of the revenue to be
reported on our financial statements. This increase in shipments is,
however, a good indicator of our success in increasing distribution
and creating awareness of our cholesterol monitor with consumers,"
stated Nikki Nessan, VP Finance.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol
monitors to consumers and healthcare professionals that provide test
results in three minutes.
The Company`s product line aids the health conscious consumer in
monitoring their risk of heart disease. By regularly testing
cholesterol at home, individuals can monitor the benefits of their
diet, exercise and/or drug therapy programs. Monitoring these benefits
can support the physician and the individual`s efforts to improve
compliance. Lifestream`s products also integrate a smart card reader
further supporting compliance by storing test results on an
individual`s personal health card for future retrieval, trend analysis
and assessment.
Lifestream`s monitors are affordable, hand-held devices that
provide users with accurate results in less than three minutes. The
product line has been designed to accommodate The Data Concern(TM)
Personal Health Card(R) allowing multiple users the ability to store
their personal results. Lifestream`s products are now available in
pharmacy and retail outlets nationwide. To find retailers that carry
Lifestream`s products, go to "Store Locator" on www.knowitforlife.com
or contact Customer Care at 888-954-LIFE. For Company information,
visit www.lifestreamtech.com.

This news release includes certain forward-looking statements
within the meaning of the safe harbor protections of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements regarding our
current business plans, strategies and objectives that involve risks
and uncertainties, and in particular statements referring to our
expectations for increased market penetration and improved gross
margins from our recently introduced second generation consumer
monitors and statements regarding our expectations that we can obtain
necessary additional financing and investment. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ from anticipated results. The forward-looking
statements are based on our current expectations and what we believe
are reasonable assumptions given our knowledge of the relevant
markets; however, our actual performance, results and achievements
could differ materially from those expressed in, or implied by, these
forward-looking statements. Factors, within and beyond our control,
that could cause or contribute to such differences include, among
others, the following: the success of our capital-raising and
cost-cutting efforts, developing and marketing relatively new medical
diagnostic devices, including technological advancements and
innovations; consumer receptivity and preferences; availability,
affordability and coverage terms of private and public medical
insurance; political and regulatory environments and general economic
and business conditions; the effects of our competition; the success
of our operating, marketing and growth initiatives; development and
operating costs; the amount and effectiveness of our advertising and
promotional efforts; brand awareness; the existence of adverse
publicity; changes in business strategies or development plans;
quality and experience of our management; availability, terms and
deployment of capital; labor and employee benefit costs; as well as
those factors discussed in our most recent Registration Statement on
Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6
- Our Management`s Discussion and Analysis," particularly the
discussion under "Risk Factors - Substantial Doubt as to our Ability
to Continue as a Going Concern" and elsewhere in our most recent
Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003,
both filed with the United States Securities and Exchange Commission.
Readers are urged to carefully review and consider the various
disclosures made by us in this report, in the aforementioned Form SB-2
and Form 10-KSB, and those detailed from time to time in our other
reports and filings with the United States Securities and Exchange
Commission that attempt to advise interested parties of the risks and
factors that are likely to affect our business.
Contacts:

Lifestream Technologies
Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)
[e-mail]

[Inkmarker]

Und wieder news von der Vermarktung:

Lifestream Technologies` Advertising and Promotion Programs Kick In; Lifestream Sees Expansion in 2005 as Advertising and Targeted Marketing Increase Sales 29%

2004-07-13 06:30 ET - News Release

POST FALLS, Idaho -- (Business Wire) -- July 13, 2004

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading
manufacturer of home cholesterol monitors and professional screening
devices, today announced that sales within a subset of its primary
retail distribution channel are up 29% from the same period last year.
"With the implementation of our radio ad campaign beginning in
March, as well as key promotional programs, Lifestream is realizing
the preliminary impact of increasing consumer awareness for its
products," noted Christopher Maus, Lifestream`s President and CEO.
"When compared to the same period last year, the subset`s retail sales
activity between mid March through mid May shows a 29% increase
verifying that Lifestream`s recent advertising and promotional
activities are showing significant improvements within targeted retail
segments. When compared with the subset`s retail sales activity for
January through mid March, Lifestream products realized a 19%
increase. Generally, sales tend to flatten after the Christmas
holiday, but continued retail sales increases reinforce the fact that
Lifestream`s efforts to raise awareness are having a material impact
on retail growth."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol
monitors to consumers and healthcare professionals that provide test
results in three minutes.
The Company`s product line aids the health conscious consumer in
monitoring their risk of heart disease. By regularly testing
cholesterol at home, individuals can monitor the benefits of their
diet, exercise and/or drug therapy programs. Monitoring these benefits
can support the physician and the individual`s efforts to improve
compliance. Lifestream`s products also integrate a smart card reader
further supporting compliance by storing test results on an
individual`s personal health card for future retrieval, trend analysis
and assessment.
Lifestream`s monitors are affordable, hand-held devices that
provide users with accurate results in less than three minutes. The
product line has been designed to accommodate The Data Concern(TM)
Personal Health Card(R) allowing multiple users the ability to store
their personal results. Lifestream`s products are now available in
pharmacy and retail outlets nationwide. To find retailers that carry
Lifestream`s products, go to "Store Locator" on www.knowitforlife.com
or contact Customer Care at 888-954-LIFE. For Company information,
visit www.lifestreamtech.com.

This news release includes certain forward-looking statements
within the meaning of the safe harbor protections of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements regarding our
current business plans, strategies and objectives that involve risks
and uncertainties, and in particular statements referring to our
expectations for increased market penetration and improved gross
margins from our recently introduced second generation consumer
monitors and statements regarding our expectations that we can obtain
necessary additional financing and investment. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ from anticipated results. The forward-looking
statements are based on our current expectations and what we believe
are reasonable assumptions given our knowledge of the relevant
markets; however, our actual performance, results and achievements
could differ materially from those expressed in, or implied by, these
forward-looking statements. Factors, within and beyond our control,
that could cause or contribute to such differences include, among
others, the following: the success of our capital-raising and
cost-cutting efforts, developing and marketing relatively new medical
diagnostic devices, including technological advancements and
innovations; consumer receptivity and preferences; availability,
affordability and coverage terms of private and public medical
insurance; political and regulatory environments and general economic
and business conditions; the effects of our competition; the success
of our operating, marketing and growth initiatives; development and
operating costs; the amount and effectiveness of our advertising and
promotional efforts; brand awareness; the existence of adverse
publicity; changes in business strategies or development plans;
quality and experience of our management; availability, terms and
deployment of capital; labor and employee benefit costs; as well as
those factors discussed in our most recent Registration Statement on
Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6
- Our Management`s Discussion and Analysis," particularly the
discussion under "Risk Factors - Substantial Doubt as to our Ability
to Continue as a Going Concern" and elsewhere in our most recent
Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003,
both filed with the United States Securities and Exchange Commission.
Readers are urged to carefully review and consider the various
disclosures made by us in this report, in the aforementioned Form SB-2
and Form 10-KSB, and those detailed from time to time in our other
reports and filings with the United States Securities and Exchange
Commission that attempt to advise interested parties of the risks and
factors that are likely to affect our business.
Contacts:

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)
[e-mail]

[Inkmarker]

Weitere Neuigkeiten:

Independent Study Shows Lifestream Technologies` Cholesterol Monitor to Be as Accurate as Physician`s Office Test; Consumers Can Trust Home Test Results

2004-07-19 06:30 ET - News Release

POST FALLS, Idaho -- (Business Wire) -- July 19, 2004

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading
manufacturer of home cholesterol monitors and professional screening
devices, today announced that an independent accuracy and precision
study was conducted by Radiant Research, Inc., comparing the
Lifestream Cholesterol Monitor against three professional methods: a
physician`s office lab system, a local independent lab, and the
Abell-Kendall method, the US government accuracy and precision
standard for all cholesterol test devices.
"It is extremely important that we determine accuracy of at-home
testing," stated Dr. Michael Davidson, Medical Director for Radiant
Research. "At-home testing provides an opportunity for patients to
assume more control of their overall health. If patients can identify
the problem early on, they can work with their physician to initiate
treatment."
This independent study was conducted at Radiant`s Tucson, Arizona,
facility under strict scientific controls with trial protocol approved
by an Institutional Review Board. The study assessed Lifestream`s home
cholesterol monitor against an independent lab, a popular physician`s
office lab system, and the CDC-controlled standard, the Abell-Kendall
technique, at a Cholesterol Reference Method Lab. A copy of the study
results are available on Lifestream`s website at
http://www.knowitforlife.com/proresources.asp or by email at
[e-mail].
"This study was motivated by recent articles, which implied that
results provided by home cholesterol test devices were inaccurate,"
stated Christopher Maus, Lifestream`s President and CEO. "These
articles` conclusions, based on non-scientific testing procedures,
were assumptive at best and conducted in a casual manner leading the
reader to an erroneous conclusion. This journalist approach misleads
the public. Although we don`t believe any particular media group would
intentionally utilize what, in scientific circles, would be considered
"junk science," we are trying to reassure the public as to what pure
science says about Lifestream`s product. The Radiant Research study`s
conclusions proved that test results obtained with Lifestream`s
cholesterol monitor were as accurate and precise as the results
obtained from a physician`s office or an independent lab."
The National Cholesterol Education Program (NCEP) has concluded
that home testing can be an important tool in improving adherence to
cholesterol programs. Separate studies indicate that as few as 30% of
patients remain on statin medication after one year. Home testing has
proven to be effective in monitoring blood pressure and glucose; now,
it is also effective in cholesterol management programs.
"The results of this preliminary study are clear and unambiguous,"
stated Jackson Connolly, Lifestream`s VP Product Development. "Under
strict scientific evaluation protocols and lab practices, the
Lifestream Cholesterol Monitor`s results prove as accurate as test
results received from a physician`s office. To further confirm this, a
number of other universities are preparing to replicate this study to
confirm the results. It is expected that the results of this expanded
study will encourage the media to use good journalistic practices
relying on scientific literature rather than relying on misleading
outcomes from nonscientific methods. We expect the expanded study
results to be submitted to important peer review journals."

About Radiant Research

Based near Seattle, Radiant Research
(http://www.radiantresearch.com) is a comprehensive clinical research
company that provides Phase I-IV clinical drug development services to
the biopharmaceutical and medical device industry. Radiant is
comprised of more than 50 wholly owned premier clinical research sites
nationwide, employing over 1,000 research professionals exclusively
focused on providing professional, high-quality comprehensive clinical
research services. In the past four years, Radiant has conducted more
than 8,400 clinical trials across 18 therapeutic specialties.
Radiant`s client list includes every major pharmaceutical company and
contract research organization and many biotechnology and medical
device companies.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol
monitors to consumers and healthcare professionals that provide test
results in three minutes.
The Company`s product line aids the health-conscious consumer in
monitoring their risk of heart disease. By regularly testing
cholesterol at home, individuals can monitor the benefits of their
diet, exercise and/or drug therapy programs. Monitoring these benefits
can support the physician and the individual`s efforts to improve
compliance. Lifestream`s products also integrate a smart card reader
further supporting compliance by storing test results on an
individual`s personal health card for future retrieval, trend analysis
and assessment.
Lifestream`s monitors are affordable, hand-held devices that
provide users with accurate results in less than three minutes. The
product line has been designed to accommodate The Data Concern(TM)
Personal Health Card(R) allowing multiple users the ability to store
their personal results. Lifestream`s products are now available in
pharmacy and retail outlets nationwide. To find retailers that carry
Lifestream`s products, go to "Store Locator" on www.knowitforlife.com
or contact Customer Care at 888-954-LIFE. For Company information,
visit www.lifestreamtech.com.

This news release includes certain forward-looking statements
within the meaning of the safe harbor protections of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements regarding our
current business plans, strategies and objectives that involve risks
and uncertainties, and, in particular, statements referring to our
expectations for increased market penetration and improved gross
margins from our recently introduced second-generation consumer
monitors and statements regarding our expectations that we can obtain
necessary additional financing and investment. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ from anticipated results. The forward-looking
statements are based on our current expectations and what we believe
are reasonable assumptions given our knowledge of the relevant
markets; however, our actual performance, results and achievements
could differ materially from those expressed in, or implied by, these
forward-looking statements. Factors, within and beyond our control,
that could cause or contribute to such differences include, among
others, the following: the success of our capital-raising and
cost-cutting efforts, developing and marketing relatively new medical
diagnostic devices, including technological advancements and
innovations; consumer receptivity and preferences; availability,
affordability and coverage terms of private and public medical
insurance; political and regulatory environments and general economic
and business conditions; the effects of our competition; the success
of our operating, marketing and growth initiatives; development and
operating costs; the amount and effectiveness of our advertising and
promotional efforts; brand awareness; the existence of adverse
publicity; changes in business strategies or development plans;
quality and experience of our management; availability, terms and
deployment of capital; labor and employee benefit costs; as well as
those factors discussed in our most recent Registration Statement on
Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item
6 -- Our Management`s Discussion and Analysis," particularly the
discussion under "Risk Factors -- Substantial Doubt as to our Ability
to Continue as a Going Concern" and elsewhere in our most recent
Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003,
both filed with the United States Securities and Exchange Commission.
Readers are urged to carefully review and consider the various
disclosures made by us in this report, in the aforementioned Form SB-2
and Form 10-KSB, and those detailed from time to time in our other
reports and filings with the United States Securities and Exchange
Commission that attempt to advise interested parties of the risks and
factors that are likely to affect our business.
Contacts:

Lifestream Technologies, Inc., Post Falls
Investor Relations Contact:
Gerri Vance, 208-457-9409 ext. 1221
[e-mail]

[connyco]

Mein Bruchstück-Englisch sagt mir, daß es positive Tests der Cholesterinmonitore von Lifestream gegeben hat ??
Die müssten drüben in USA mehr in die Werbung gehen, um die Geräte einem großen Publikum bekannt zu machen. Dann könnte der Kurs endlich mal wieder über die 0,05 USD steigen und wir, die an dem Papier festgehalten haben, mal wieder Licht im Norden sehen

[Inkmarker]

# 64

Ich glaube, dass LFTC im Augenblick genug Werbung macht. Man sieht ja auch an dem Umsatzanstieg, dass sich die Werbung in der Hinsicht schon bezahlt gemacht hat.

Entscheidend dürfte m.E. sein, ob die aufkommende Nachfrage auch befriedigt werden kann. Dies war ja das Ziel der letzten Kapitalerhöhung. Sollte dies gelingen, und dauerhaft hohe Stückzahlen abgesetzt werden, steht LFTC vor einer Neubewertung.


Grüße Inkmarker

[connyco]

# 64
so soll es sein !!

[ustrading]

heute noch gar kein Handel bei den Amis .... was ist da los

[Inkmarker]

Handel läuft schon. Nur in die falsche Richtung...

[Inkmarker]

NEWS:

Lifestream Announces RxSchool`s Launch of National Pharmacy Education Program; Continuing Education Program Focuses on Increasing Patient Adherence Through Home Monitoring

2004-07-27 06:30 ET - News Release

POST FALLS, Idaho -- (Business Wire) -- July 27, 2004

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading
manufacturer of home cholesterol monitors and professional screening
devices, today announced that RxSchool is releasing a new pharmacy
continuing education program designed to provide pharmacists with a
greater understanding of the role home cholesterol monitoring plays in
helping patients manage their cholesterol levels and improve overall
patient compliance.
Steve Croke, President of RxSchool, stated, "Those patients on
cholesterol-lowering drugs rarely stay on them long enough to derive
the cardiovascular benefits the therapy can provide. The science is
clear that one effective method is for patients to get regular
feedback from self monitoring. To educate the pharmacist on this
science is key to making a change in adherence. This is one of our
best CE programs yet, and we are very excited about being able to
provide pharmacists with an opportunity to adopt new tools in their
effort to control heart disease."
"With only 30% of patients remaining on statin drugs after the
first year, the value of improving patient adherence is undeniable,"
said Christopher Maus, Lifestream`s President and CEO. "Statin drugs,
considered by many to be extremely important for Americans`
cardiovascular health, is the largest drug sector, exceeding $17
billion a year. Monitoring cholesterol at home is a proven method for
enhancing patient adherence. It is very important that pharmacists
understand the nature and value of patient self monitoring."
"We are very pleased that RxSchool, one the nation`s premier
providers for continuing education, has elected to provide this
educational campaign for cholesterol management," stated Ed Siemens,
Lifestream`s COO. "These efforts will provide pharmacists throughout
the U.S. with additional knowledge to support their patients in
managing cholesterol through home monitoring. The role of home
monitoring in the continuum of care is growing in importance. We are
pleased that pharmacists, 120,000 strong, will have such a valuable
educational resource."

About RxSchool.com

A division of Pharmacy Choice, Inc., RxSchool is an e-learning web
portal and software solutions company that provides a comprehensive
suite of educational courses and training tools for the health care
industry. The RxSchool website is utilized by tens of thousands of
pharmacists, pharmacy technicians, physicians and nurses who practice
in hospital, retail, managed care, long-term care, private practice
and various other health care settings. As a leader in educational
solutions for the industry, RxSchool is supported by pharmaceutical
industry sponsors and endorsed by industry associations, employers and
educational institutions. For more information about RxSchool or
Pharmacy Choice, please visit their respective web sites at
www.rxschool.com or www.pharmacychoice.com

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol
monitors to consumers and healthcare professionals that provide test
results in three minutes.
The Company`s product line aids the health-conscious consumer in
monitoring their risk of heart disease. By regularly testing
cholesterol at home, individuals can monitor the benefits of their
diet, exercise and/or drug therapy programs. Monitoring these benefits
can support the physician and the individual`s efforts to improve
compliance. Lifestream`s products also integrate a smart card reader,
further supporting compliance by storing test results on an
individual`s personal health card for future retrieval, trend analysis
and assessment.
Lifestream`s monitors are affordable, hand-held devices that
provide users with accurate results in less than three minutes. The
product line has been designed to accommodate The Data Concern(TM)
Personal Health Card(R), allowing multiple users the ability to store
their personal results. Lifestream`s products are now available in
pharmacy and retail outlets nationwide. To find retailers that carry
Lifestream`s products, go to "Store Locator" on www.knowitforlife.com
or contact Customer Care at 888-954-LIFE. For Company information,
visit www.lifestreamtech.com.

This news release includes certain forward-looking statements
within the meaning of the safe harbor protections of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements regarding our
current business plans, strategies and objectives that involve risks
and uncertainties and, in particular, statements referring to our
expectations for increased market penetration and improved gross
margins from our recently introduced second-generation consumer
monitors and statements regarding our expectations that we can obtain
necessary additional financing and investment. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ from anticipated results. The forward-looking
statements are based on our current expectations and what we believe
are reasonable assumptions given our knowledge of the relevant
markets; however, our actual performance, results and achievements
could differ materially from those expressed in, or implied by, these
forward-looking statements. Factors, within and beyond our control,
that could cause or contribute to such differences include, among
others, the following: the success of our capital-raising and
cost-cutting efforts, developing and marketing relatively new medical
diagnostic devices, including technological advancements and
innovations; consumer receptivity and preferences; availability,
affordability and coverage terms of private and public medical
insurance; political and regulatory environments and general economic
and business conditions; the effects of our competition; the success
of our operating, marketing and growth initiatives; development and
operating costs; the amount and effectiveness of our advertising and
promotional efforts; brand awareness; the existence of adverse
publicity; changes in business strategies or development plans;
quality and experience of our management; availability, terms and
deployment of capital; labor and employee benefit costs; as well as
those factors discussed in our most recent Registration Statement on
Form SB-2 filed June 10, 2004, and in "Item 1 -- Our Business," "Item
6 -- Our Management`s Discussion and Analysis," particularly the
discussion under "Risk Factors -- Substantial Doubt as to our Ability
to Continue as a Going Concern" and elsewhere in our most recent
Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003,
both filed with the United States Securities and Exchange Commission.
Readers are urged to carefully review and consider the various
disclosures made by us in this report, in the aforementioned Form SB-2
and Form 10-KSB, and those detailed from time to time in our other
reports and filings with the United States Securities and Exchange
Commission that attempt to advise interested parties of the risks and
factors that are likely to affect our business.
Contacts:

Lifestream Technologies, Inc., Post Falls
Investor Relations:
Gerri Vance, 208-457-9409 ext. 1221
[e-mail]

Mal schauen, wie der Kurs darauf heute reagiert.

[connyco]

Bisher haben die Amis anscheinend noch nichts gelesen, Umsatz absolut unbedeutend, Kurs"sprung" 0,002 USD reisst mich auch nicht vom Hocker. Aber was nicht ist, das kann --soll-- noch werden !!

[Inkmarker]

Mal wieder etwas NEUES von der Vermarktung:

Lifestream Technologies Presents on National Shopping Network; Lifestream`s Success Expands National Television Exposure
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222 (Investor Relations)

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors and professional screening instruments, announced that the Lifestream Cholesterol Monitor with Health Risk Assessment (HRA) will be sold exclusively on a national shopping network over the next two months.

"Due to our previous success, we have been selected to present our newest product in monthly airings on one of television`s major shopping networks. With the network`s distribution exceeding 80 million homes, this is a unique opportunity to continue to build category awareness and increase revenues," said Christopher Maus, Lifestream`s President and CEO. "Our Cholesterol Monitor with Health Risk Assessment (HRA) brings new meaning to individuals seeking to take control of their heart health. Along with cholesterol results, numerous factors related to heart health are assessed giving individuals a clear and meaningful outcome of personal choices and changes that can be made to improve a person`s level of health."

"Lifestream obtained a 510(k) clearance to market its new technology from the FDA this past June," stated Jack Connolly, VP Product Development. "This revolutionary technology enables individuals to not only track cholesterol levels, but to calculate their personal risk of heart attack, obesity, etc. After taking a three-minute cholesterol test, you only need to input a few additional risk factors, including gender, age, height, weight, diabetic status, smoker/non-smoker, systolic and diastolic blood pressure, and HDL breakout from a recent lipid profile. The HRA shows the user`s risk of a heart attack. In addition, the monitor allows the user to evaluate different outcome models by altering the inputs (i.e., smoker vs. non-smoker), which supports an individual`s efforts to change in a comprehensive way."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management`s Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


Allerdings keine positive Kursreaktion. Es sollten endlich mal ein paar Zahlen auf den Tisch gelegt werden.

Grüße Inkmarker

[connyco]

Meine wenigen Englichkenntnisse reichen nicht, um den kompletten Inhalt zu verstehen, aber soviel ich verstehen kann, gibts wohl nichts grundlegend Neues zu berichten ??
Nichts Negatives ist ja auch schon positiv, oder ???

[Inkmarker]

#72

Leider werden Nachrichten bezüglich einer positiven Vermarktung nicht mehr mit Aufschlägen honoriert.

Ich glaube, dass es erst dann wieder hoch geht, wenn sich die Vermarktung auch in konkreten Zahlen niederschlägt.

Ich werde vielleicht noch ein zweites Mal nachkaufen, in der Hoffnung, dass die Vermarktung tatsächlich ein Erfolg wird.


Grüße Inkmarker

[connyco]

# 73
Danke Inkmarker. Ich habe auch schon mal überlegt, ob ich noch nachkaufen soll. Aber dies habe ich bereits 2 x gemacht und bin jetzt mit 100.000 Stück dabei zum Kurs von 0,08 €.
Es fällt mir schwer, nach diesen 8.ooo Euro soviel Vertrauen aufzubringen !!

[Inkmarker]

#74

Das kann ich gut verstehen. Allerdings ist fraglich, wie hoch die Aktie bei einem Ausbruch nochmal steigen wird. D.h., ob wir unsere Einstiegsnivaus wiedersehen.

Im Augenblick kann man schwer sagen, wohin der Kurs gehen wird.

Wenn man jetzt einsteigt oder zukauft, kann der Kurs auch morgen nochmal um 50% abstürzen. Aber so ist es eben bei allen OTC-Werten.

Ich versuche gerade bei CNEX und SBIO nochmal billig ein paar Stücke nachzukaufen. Sollte dies nicht gelingen, werde ich mein Glück nochmal mit LFTC versuchen.

Grüße Inkmarker

[Inkmarker]

N E W S :

US Appeals Court Overturns Decision of District Court on HDL Infringement; Lifestream Technologies Prevails in Its Appeal to the US Court of Appeals for the Federal Circuit
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222 (Investor Relations)

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors and professional screening instruments, announced that the U.S. Court of Appeals for the Federal Circuit has reversed an adverse District Court decision against Lifestream and remanded it back to the District Court for further proceedings.

Lifestream asserted that a test strip being marketed by Polymer Technology Systems, Inc., which performed measurements of HDL cholesterol, infringed a patent owned by Lifestream. The U.S. District Court for the District of Idaho had ruled that Polymer`s test strips did not infringe that patent. The Court of Appeals reversed the District Court`s ruling in Lifestream`s favor and remanded the matter back to the District Court.

"We are pleased the Court of Appeals overturned the District Court decision. We believe that our HDL patent has significant value," stated Lifestream`s President and CEO, Christopher Maus. "In an effort to bring this matter to a conclusion, we have entered into a Letter of Intent with Polymer to come to an agreement to resolve this matter through a licensing arrangement and provide adequate protection of Lifestream`s proprietary rights. Ending this costly litigation will allow us to better focus our resources on developing and expanding product awareness."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

Although we believe our claims are well founded in law and fact and that the defendant`s counterclaims and defenses are baseless, the outcome of this litigation cannot be predicted with certainty. Should the District Court on retrial not rule in Lifestream`s favor, it may be unsuccessful in collecting future royalties from parties utilizing this technology, which may result in the reduction of the net realizable value of the patent.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed June 10, 2004, and in "Item 1 - Our Business," "Item 6 - Our Management`s Discussion and Analysis," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2003, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.





Copyright © 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2004 Interest!ALERT All rights reserved.


Der Kurs kann leider wieder nicht wirklich positiv reagieren.

Grüße Inkmarker

[Inkmarker]

Erste Zahlen sind da. Die Umsätze sind im Juli im Vergleich zum Vorjahr um 169% gestiegen.


Lifestream Technologies Announces July Shipments Grew 169%; Numbers for July 2004 Indicate Lifestream Exceeds Shipment Goals
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors and professional screening instruments, announced today that its shipments for the month of July are up 169% over the same period in 2003. Preliminary numbers indicate $581,486 shipped during July 2004 as compared to $216,052 for the previous July.

"It appears that our increased distribution, acceptance by the viewers of the television shopping network and other marketing efforts are increasing awareness and impacting demand at the retail shelf," said Christopher Maus, President and CEO. "These shipment numbers indicate the Company is on target as we begin the next phase of our rollout strategy. Our new Health Risk Assessment product, which began limited rollout in September, will further aid the health conscious consumer in creating a healthier lifestyle. Lifestream continues to grow the market with expanded distribution. We will continue our efforts to increase product awareness and support our retailers as we now have what can be truly considered national distribution."

"This increase in shipments is a good indicator of our success in increasing distribution and creating awareness," stated Nikki Nessan, VP, Finance. "However, Lifestream`s revenue recognition policy does not necessarily result in revenue recognition at the time product is shipped. As a result, shipments are not an indicator of the revenue to be reported on our financial statements."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices. The product line has been designed to accommodate the Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.

[Inkmarker]

N E W S :

Lifestream Technologies Number One Selling Item in Its Category on National Shopping Network; No. 1 Best Selling Item in Healthy Living Aids During the 24-Hour Period of Airing
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors and professional screening instruments, announced today that its Cholesterol Monitor with Health Risk Assessment (HRA) was posted as the best selling item in Healthy Living Aids during the 24-hour period in which it was presented.

"Because of this great response, Lifestream`s product will air again in October. If our product continues to do well, Lifestream would like to pursue a more regular schedule after the holiday season," said Christopher Maus, Lifestream`s president and CEO. "With the network`s distribution exceeding 80 million homes, the opportunity to present on a more regular basis would continue to build awareness of our product and increase revenues. Since our new HRA product is being sold exclusively on this network, the Company has a great opportunity to get its marketing message out prior to rolling out to other classes of trades."

Lifestream obtained a 510(k) clearance for its new technology from the FDA this past June. This technology enables individuals to not only track cholesterol levels, but to calculate their personal risk of heart attack. After taking a three-minute cholesterol test, the user need only input a few additional risk factors, including gender, age, height, weight, diabetic status, smoker/non-smoker, systolic and diastolic blood pressure, and HDL breakout from a recent lipid profile. The HRA shows the user`s risk of a heart attack. In addition, the monitor allows the user to evaluate different outcome models by altering the inputs (i.e., smoker vs. non-smoker), which supports and individuals efforts in a compressive way."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices. The product line has been designed to accommodate the Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.

Wann kommt endlich der Durchbruch auch beim Aktienkurs?

[cyba]

Lifestream Technologies Announces August Shipments Grew 124%

Wednesday October 13, 6:30 am ET

Numbers for August continue to exceed shipment goals

POST FALLS, Idaho--(BUSINESS WIRE)--Oct. 13, 2004--Lifestream Technologies, Inc. (OTCBB:LFTC - News), the leading supplier of cholesterol monitors and professional screening instruments, announced today that its shipments for the month of August were up 124% over the same period in 2003. Preliminary numbers indicate $429,141 of product shipped during August 2004, as compared to $191,766 for the previous August.

"We believe disclosure of these monthly shipment numbers addresses investor questions and are indicative of our broad-based efforts, particularly in marketing," said Christopher Maus, President and CEO. "Since the shipment change is so apparent, we thought it appropriate to convey that number prior to the end of the quarter. It appears our increased distribution, acceptance by the television shopping network`s viewers, and other marketing efforts are having an impact on our retailers. Shipment numbers indicate the retailer is either increasing inventory or increasing sell-through at the retail shelf, which moves the medical device category in the right direction."

Lifestream`s revenue recognition policy does not necessarily result in revenue recognition at the time product is shipped. As a result, shipments are not an indicator of the revenue to be reported on our financial statements.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices. The product line has been designed to accommodate the Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.
Contact:

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)


Source: Lifestream Technologies, Inc.

[connyco]

Solange die Yankee`s den Wert nicht neu entdecken, bleibt bei uns "Tote Hose"

[Chris8888]

@all,


ich wollte mal von Euch wissen,ob Ihr die Zukunft des Wertes über die nächsten 2 Jahre positiv betrachtet?
Speziell auf meinen Fall auch bezogen würde ich mich über Meiungsäußerungen freuen.....

Ich hatte mal vor einem Jahr 3000 stk zu 0,21 € gekauft und würde gerne nach den Verkaufszahlen der letzten 2 Monaten nachkaufen,um zu verbilligen!Denkt ihr es lohnt sich,oder würdet ihr erst wieder aufspringen,wenn positives cashflow verhanden ist?

Danke

MfG

[Inkmarker]

@Chris8888!

Ist m.E. schwer zu sagen, wo sich der in den nächsten zwei Jahren hinbewegen wird.

Einerseits scheint LFTC in den letzten Monaten ja ganz gut ihre Monitore verkauft zu haben.

GUT

Auf der anderen Seite muss aber auch sehen, dass die Firma Anfang des Jahres Wandelanleihen im beträchtlichen Umfang heraus gegeben hat. Diese können, wenn ich mich nicht täusche im nächsten Jahr gewandelt werden.

EHER NEGATIV

Zu dem letzten Punkt habe ich auch am Anfang des Threads etwas geschrieben (d.h. ich habe mich mit den damaligen AD-HOC-Mitteilungen auseinandergesetzt). Kannst ja mal nachlesen.


Ich denke, dass wenn die Aktie von ein paar Börsenbriefen (wieder)entdeckt wird, könnten wir durch aus vielleicht um 200 - 300 Prozent steigen. Falls dies nicht geschieht, wird der Kurs wohl eher seitwärts tendieren.

Bin übrigens selbst am überlegen noch ein zweites Mal nachzukaufen.

Ich hoffe meine Meinung konnte Dir etwas helfen.

Grüße Inkmarker

[Chris8888]

Hi Inkmaker,


danke schonmal für Deine Meinung...ich stimme Dir überein,obwohl ich bei profitablen Geschäft von mehr als 200-300 % Steigerung ausgehe...


Habe mich mal auf der Seite von Lifestream(bei News)die Bewertung der Firma durch HPC Capital Research durchgelesen und ich finde es ist ausgewogen geschrieben...lest es mal durch!

Des weiteren bin ich auf die Verkaufsseite von LFTC gestossen...www.knowitforlife.com

Auch interessant,oder!

Ich mach mir mal Gedanken über ein Re-Invest

Über weitere Meinungen zu meiner Situation bin ich dankbar


MfG

[Inkmarker]

N E W S - 21.10.2004:

Lifestream Technologies Announces First Quarter FY2005 Shipments Increased 108%; Retailers continue to build inventory and sales
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors, announced today that preliminary numbers indicate shipments for the first quarter of FY2005 increased 108% over shipments for the first quarter of FY2004.

"We see the increase in shipment numbers as a move by our customers to build inventory and to cover retail sales. September shipment numbers are indicative of our broad-based efforts, particularly in marketing and increased distribution," said Christopher Maus, President and CEO. "It appears our increased distribution, acceptance by the television-shopping network`s viewers, and other marketing efforts are having an impact on our retailers. Shipment numbers indicate the retailer is either increasing inventory or supporting sell-through."

Lifestream`s revenue recognition policy does not necessarily result in revenue recognition at the time product is shipped. As a result, shipments are not an indicator of the revenue to be reported on the financial statements.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices. The product line has been designed to accommodate the Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.





Copyright © 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2004 Interest!ALERT All rights reserved.

[Inkmarker]

NEWS, und diesmal geht der Kurs mal wieder richtig ab!

Im Augenblick: + 53 %; Gerade heute habe ich eine Order eingegeben und wollte nach dem Kurssturz gestern nochmal billig ein paar Stücke abgreifen. War wohl leider nichts.


Hier die N E W S:

Lifestream Technologies Ranked 40th Fastest Growing Technology Company in North America on the 2004 Deloitte Technology Fast 500



POST FALLS, Idaho--(BUSINESS WIRE)--Nov. 4, 2004--

Lifestream is rated in the top 50 out of 500 companies

Lifestream Technologies, Inc. (OTCBB:LFTC), the leading supplier of cholesterol monitors, announced today that it ranked Number 40 on the 2004 Deloitte Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on a percentage of revenue growth over five years from 1999-2003. Lifestream`s revenues grew 6,846% during this period.

"Achieving sustained revenue growth of 6,846% over five years is a tremendous accomplishment during a difficult period for the technology sector," said Mark A. Evans, national managing partner of Deloitte`s Technology, Media & Telecommunications Group. "Lifestream`s phenomenal growth puts it in select company."

Lifestream`s CEO, Christopher Maus, credits the introduction of its cholesterol monitor to the consumer market and increased retail presence with the Company`s 6,846% revenue growth over the past five years. "We are honored to be rated so high on the Deloitte Technology Fast 500," stated Maus. "Our success has been driven by consumers taking more responsibility for their heart health. We look forward to continuing revenue growth by increasing distribution channels and building consumer awareness for our product."

Fast 500 Selection and Qualification

The Fast 500 list is compiled from Deloitte`s 19 regional North American Fast 50 programs, nominations submitted directly to the Fast 500, and public company database research. Winners are selected based on the percentage of growth in revenues from 1999 to 2003. To be considered, Fast 500 entrants must have had 1999 operating revenues of at least $50,000 USD and $75,000 CD for the United States and Canada, respectively; and 2003 operating revenues must be at least $1 million USD or CD.

Entrants must also be public or private companies headquartered in North America and must be a "technology company," defined as a company that owns proprietary technology that contributes to a significant portion of the company`s operating revenues or devotes a significant proportion of revenues to the research and development of technology. Using other companies` technology in a unique way does not qualify.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other`s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu," or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Tax LLP, and their subsidiaries), and not by Deloitte & Touche USA LLP.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream TechnologiesGerri Vance, 208-457-9409 ext. 1222 (Investor Relations)
[e-mail]

SOURCE: Lifestream Technologies

[Inkmarker]

JETZT: 150 % im plus!

[cyba]

klasse!!!! wo führt das nur hin?
ich warte wohl noch mit dem autokauf

[africanus]

mal schaun ob das was bewirkt.
wären eigentlich gute news.


Lifestream Technologies and Polymer Technology Systems Settle Patent Litigation; Lifestream and Polymer Work Together to Create Opportunities and End Litigation
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1222 (Investor Relations)

Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, announced that it has settled its patent litigation with Polymer Technology Systems, Inc., relating to Lifestream`s 716 Patent (HDL technology). As part of the settlement of the parties` claims against each other, Polymer has agreed to make royalty payments to Lifestream in connection with certain of Polymer`s future sales of products incorporating Lifestream`s 716 Patent.

"The US Court of Appeals` decision earlier this year provided an opportunity for both parties to resolve the issues surrounding this litigation in a way beneficial for both companies," said Christopher Maus, Lifestream`s President and CEO. "We have entered into a settlement agreement allowing Polymer to use Lifestream`s HDL patent for the term of that patent, as well as allowing Lifestream to protect the benefits of the HDL patent, which include future licensing rights. This resolution ends the litigation, is in the parties` best interests, and will add value to both companies as we continue to develop our respective markets. Our agreement allows both companies to work more closely together on future endeavors for the benefit of both."

"We are pleased to have come to a solution suitable for both Companies," states Bob Huffstodt, President and CEO of Polymer Technology Systems, Inc. "This settlement is in the best interests of our shareholders, as well as our present and future customers. Our resources can now be better directed towards our business as we look forward to market expansion. Both our companies are now better positioned to take advantage of the expanding opportunities within the lipid testing market."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

About Polymer Technology Systems, Inc.

Polymer Technology Systems, Inc. (PTS), is a privately held, emerging medical device company that has developed a family of proprietary products to rapidly and accurately test cholesterol and other lipid levels in the blood to help identify and single out the millions worldwide who are at risk for cardiovascular disease -- the leading cause of death in the U.S. today -- so that therapeutic lifestyle changes and drug treatment programs will be sought and followed.

PTS` unique technology has led to the first and only FDA-cleared and CLIA-waived blood testing solution that is suitable for both the professional point of care testing market and the home testing market. The PTS system consists of the CardioChek(TM) family of instruments, and PTS PANELS(TM) Test Strips and can test total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, as well as other analytes.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.

quelle: http://www.otcbb.com

[Inkmarker]

Na es geht zumindest leicht aufwärts.

[connyco]

Nach kurzem Strohfeuer wieder "tote Hose" ??

[Inkmarker]

N E W S :

Preventive Cholesterol Screening Reimbursed by Medicare; Lifestream Technologies sees increased demand for its products



POST FALLS, Idaho--(BUSINESS WIRE)--Dec. 15, 2004--The Centers for Medicare & Medicaid Service (CMS) recently announced its 2005 Physician Fee Schedule, which provides for access to preventive cholesterol screening for Medicare-eligible beneficiaries. Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, commends the Centers for Medicare and Medicare Service for its actions, which we believe significantly improves the quality of healthcare for America`s seniors.

Beginning in January 2005, all Medicare beneficiaries will have access to cholesterol screening to detect early risk of cardiovascular disease. Tests could be covered up to 6 times a year. Additionally, all new Medicare members are covered for an initial physical exam. Previously, Medicare patients were covered for cholesterol tests only if they had heart disease, diabetes or another disorder associated with elevated cholesterol levels.

"The government has taken a significant step by supporting pre-emptive testing to detect those Medicare patients at risk due to elevated cholesterol levels," said Christopher Maus, President and CEO of Lifestream. "Because cardiovascular disease is the number one killer in America, cholesterol screening is vitally important. Lifestream applauds Congress and the Centers for Medicare & Medicare Service for adding preventive cholesterol screening as a covered benefit. Our professional cholesterol monitor is perfect to perform a quick and accurate non-fasting cholesterol test for screening patients. Lifestream is well positioned to support proactive healthcare professionals who support this initiative."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream TechnologiesGerri Vance, 208-457-9409, ext. 1222 (Investor Relations)

SOURCE: Lifestream Technologies


Wann kommt endlich auch beim Kurs mal der Durchbruch? Das Warten nervt ganz schön, oder?

Grüße Inkmarker

[connyco]

Aus dem Weihnachtsurlaub gesund zurück. Leider ist eine "Gesundung" bei Lifestream nicht festzustellen.
Der Kurs ist resistent gegen gute Nachrichten.
Halten oder ca 6.0 T€ Verlust realisieren ???? : (

[Inkmarker]

N E W S - Aktienkurs + 16%

The FDA Schedules Hearing On Over-the-Counter Petition for Cholesterol Lowering Drug



POST FALLS, Idaho--(BUSINESS WIRE)--Jan. 6, 2005--Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, fully supports government and industry efforts to curb cardiovascular disease through proven methods by giving more control of preventive healthcare decisions to individuals. The FDA will be considering a petition to make certain statin lowering drugs available as over-the-counter medications at a hearing scheduled for January 13 and 14, 2005, in Washington, D.C.

"After years of assessing the value of statin drugs in lowering cholesterol, along with supporting lifestyle changes, the FDA has agreed to hear a major pharmaceutical company`s petition to move its statin drug from a prescriptive to a non-prescriptive status at retail stores," said Christopher Maus, Lifestream`s CEO. "In a previous hearing, the FDA comments addressed the consumer`s ability to know and track their cholesterol number. If the FDA finds that this statin drug is suitable for non-prescriptive consumer use, Lifestream sees a significant opportunity that could open the floodgates for monitoring cholesterol at home or at the point of care. This increased awareness for regular monitoring would be most conducive in supporting all cholesterol lowering programs through positive feedback and, thus, the greater likelihood of compliance."

"We look forward to supporting the efforts of individuals, industry, government and healthcare providers in their efforts to control the number one cause of premature death in the country," Maus continued. "Those efforts can be greatly served by consumers monitoring their cholesterol with the Lifestream home cholesterol monitor."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream Technologies, Inc.Gerri Vance, 208-457-9409, ext. 1221 (Investor Relations)

SOURCE: Lifestream Technologies, Inc.

[Inkmarker]

N E W S :

Lifestream`s CEO to Testify at FDA Hearing Considering Over-the-Counter Petition for Cholesterol Lowering Drugs; Maus to Testify on the Impact of Home Cholesterol Testing



POST FALLS, Idaho--(BUSINESS WIRE)--Jan. 13, 2005--Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, is scheduled to testify at the FDA hearing considering an over-the-counter petition for cholesterol lowering drugs. Christopher Maus will address the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) during the public comment period on Friday morning, January 14.

"Lifestream`s home cholesterol monitor can have a material impact in the FDA`s consideration of this petition," said Maus. "I look forward to this opportunity to address any testing concerns the FDA may have, as the benefit of home testing on an individual`s effort to take control by personal health management is acknowledged. With Lifestream`s affordable, easy and accurate suite of testing products, it is well positioned to support the public`s desire to take control of their cholesterol levels. We support government and industry efforts to give more control of preventive health care decisions to individuals."

"Lifestream`s new cholesterol monitor with Health Risk Assessment takes testing one step further by giving an individual the ability to understand combined risk factors and the effects those factors may have on their heart health as defined in the NCEP ATP III guidelines," Maus stated. "Recently cleared by the FDA, Lifestream`s cholesterol monitor with HRA supports efforts to expand cholesterol management programs. The NCEP ATP III recommends home testing as an important tool for individuals as part of their professional healthcare program. Regardless of an individual`s choice of lifestyle changes or the use of prescriptive or non-prescriptive therapies, monitoring cholesterol is a key factor for meaningful outcomes."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 -- Business," "Item 6 -- Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors -- Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream Technologies, Inc.Gerri Vance, 208-457-9409 ext. 1222

SOURCE: Lifestream Technologies, Inc.

[Inkmarker]

Und wieder NEWS; Kurs unverändert.


CORRECTING and REPLACING Lifestream Unveils Prototype for New Low Cost Monitor; Concept Product Unveiled at Recent FDA Hearing
POST FALLS, Idaho

Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1221

First graph, first sentence of release, the ticker should read: (OTCBB:LFTC) (sted (AMEX:KFL)).

The corrected release reads:

LIFESTREAM UNVEILS PROTOTYPE FOR NEW LOW COST MONITOR; CONCEPT PRODUCT UNVEILED AT RECENT FDA HEARING

Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, unveiled a concept product at the recent FDA hearing on an over-the-counter petition for cholesterol lowering drug. Lifestream has filed a patent application for its new product that reduces the cost for devices used for both the pharmacy and home testing. The technology under development looks like a computer mouse and embodies Lifestream`s optic module and strip holder but uses a PC for the balance of the functionality.

"Lifestream is continually looking for ways to reduce the cost to our customers, as well as provide greater functionality for consumers and healthcare providers alike," said Christopher Maus, Lifestream`s President and CEO. "We are exploring a prototype product that allows a user to plug a "cholesterol mouse" into their PC with all functions actually performed by the computer hardware. The product`s cost is reduced by eliminating LCD displays, microprocessors and keypads. Since the mouse is connected to the computer for its functionality, i.e., the data tracking software, the Health Risk Assessment, and data storage, information transfer to healthcare providers is quick, easy, transparent and simple. This technology would allow for easy software expansion to minimize the dating of any technology. Along with weighing this product`s value in the marketplace, we are currently evaluating production, features, and if and when the product will debut. Lifestream realizes the impact home testing has on an individual`s efforts to take control of their own health management program, and we look forward to bringing new products to the marketplace when they are determined to be suitable."

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

In addition to the professional monitor, the Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in the post effective amendment No. 1 to our Registration Statement on Form SB-2 filed December 10, 2004, and in "Item 1 - Business," "Item 6 - Management`s Discussion and Analysis and Plan of Operations," particularly the discussion under "Risk Factors - Substantial Doubt as to our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report and in the aforementioned Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.





Copyright © 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
News Copyright © 2005 Interest!ALERT All rights reserved.

[Inkmarker]

Nachtrag einer Meldung vom 08.02.2005:


Lifestream Technologies Signs Agreement to Sell Intellectual Property to LifeNexus
Tuesday February 8, 6:30 am ET
Lifestream Sees a Bright Future for Personal Health Card


POST FALLS, Idaho--(BUSINESS WIRE)--Feb. 8, 2005-- Lifestream Technologies, Inc. (OTCBB:LFTC - News), a leading supplier of cholesterol monitors, announced today that it has assigned the intellectual property of its subsidiary, Secured Interactive Technologies, to LifeNexus, Inc.
ADVERTISEMENT


"We are pleased to have this opportunity to receive a benefit from the transfer of our smart card technology since our current resources are being focused on our core business," stated Christopher Maus, Lifestream`s CEO. "This technology, which has no material value to the Company, has not been commercialized as market conditions were not conducive to support the costs related to an effective rollout. With national attention focused on revamping the healthcare information system, we believe this sale provides the most favorable opportunity for Lifestream and its shareholders. LifeNexus has proposed an innovative approach, a portable medical record in concert with powerful healthcare financial services, to create a viable opportunity for commercializing this technology. We look forward to profiting from its success."

"I look forward to working directly with LifeNexus to make this proposition successful. It brings considerable value to consumers as it is a universal solution for the portability of medical records," said Maus.

LifeNexus, Inc., is a recently organized, privately-held company focused on the development and marketing of personal healthcare on a smart card platform incorporating emergency medical information, emergency medical insurance, accidental life and other financial products.

Lifestream has entered into an agreement whereby, upon completion of LifeNexus` financing, Lifestream will receive a 49% equity position in LifeNexus and rights to the technology will transfer to LifeNexus. Maus is required by LifeNexus to facilitate the early phase of product development and it has, therefore, entered into an independent agreement wherein Maus will receive compensation as a member of the board of directors of LifeNexus. No changes are foreseen in his responsibilities at Lifestream.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

The Company`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate The Data Concern(TM) Personal Health Card® allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed January 12, 2005, and in "Item 1 - Business," "Item 6 -- Management`s Discussion and Analysis or Plan of Operation," particularly the discussion under "Risk Factors - Substantial Doubt regarding our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.



--------------------------------------------------------------------------------
Contact:
Lifestream Technologies, Inc.
Gerri Vance, 208-457-9409 ext. 1221



--------------------------------------------------------------------------------
Source: Lifestream Technologies, Inc.

[connyco]

Umsätze in Deutschland: nicht der Rede wert !!
Umsätze/Kurse in USA: seitwärts/abwärts !
Der Vertrieb der Monitore lässt sehr zu wünschen übrig, die Kosten laufen weiter, d.h.: aussteigen, solange wenigstens noch ein paar Cent gezahlt wird (Verkauf in USA, da in Deutschland keine Käufer vorhanden !!)

[connyco]

Die Kurse nähern sich immer mehr dem Nullpunkt. Ob Lifestream wohl noch einen Übernehmer findet oder --noch in diesem jahr-- liquidiert wird. ???

[regio346]

Ist hier überhaupt noch jemand investiert?????
Ich glaube der Zug ist abgefahren, da kommt nichts mehr.

[Chris8888]

Hallo,


ich bin noch drin,mit einem KK von 0,03 ct...ich warte einfach ab....Risiko ist halt dabei...aber ich kann mir nicht vorstellen,das die ganz pleite gehen!


Um Meinungen wird gebeten

[Inkmarker]

An eine Pleite glaube ich auch nicht.

Mit der nächsten guten Meldung geht`s auch schnell wieder 100% nach oben.

Immer fällt die Aktie nur unter geringen Umsätzen, so dass man davon ausgehen kann, dass die Firma selbst keine Aktien schmeißt, wie andere Firmen dies tun.

[regio346]

Schlusskurs an der OTCBB von 0.016, was soll man da noch zu sagen.
Vielleicht sind die Amis doch nicht so gesundheitsbewußt
eingestellt wie man sich erhofft hatte und kaufen das Gerät nicht.

Im Euroland könnte ich mir bessere Absatzmöglichkeiten vorstellen. Obwohl der Amerikanische Markt enormes
Potenzial birgt.

[Inkmarker]

Das Problem ist m.E. bei LFTC die ausstehende Wandelanleihe.

Wenn ich mich noch recht entsinne läuft die Frist Anfang des nächsten Jahres aus. Das Problem ist, der Kurs bei der Ausgabe der Anleihe lag bei über $ 0,04. Also wird wohl keiner wandeln, was zur Folge hat, dass LFTC möglicherweise Aktien schmeißen muss, um an das Geld zur Rückzahlung zu kommen.

Wer etwas zu diesem Thema wissen will, kann ja mal am Anfang des Threads nachlesen.

Die Absatzmöglichkeiten in Euroland schätze ich grundsätzlich auch positiv ein. Allerdings wird die Markterschließung nur mit einer Vertriebsmannschaft möglich sein, und die kostet wieder Geld.

Es ist schon ein Dilema.

Aber die Hoffnung stirbt zuletzt, denn erstens kommt es anders und zweitens als man denkt.

[Inkmarker]

Ich will mal noch eine Meldung vom 05.04.2005 nachreichen.

Lifestream Appoints Ed Siemens to Its Board; A Twenty-Year Veteran of Retail Markets Joins Board of Directors



POST FALLS, Idaho--(BUSINESS WIRE)--April 5, 2005--Lifestream Technologies, Inc. (OTCBB:LFTC), a leading supplier of cholesterol monitors, today announced the appointment of Edward R. Siemens to its Board of Directors. Before joining Lifestream, Siemens was President of Omron Healthcare, Inc., the leading marketer of home-use digital blood pressure monitors. His career has focused on the creation and implementation of sales and marketing programs, as well as oversight of operations.

"Ed brings additional expertise in marketing, sales and good business practices to Lifestream`s Board," said Christopher Maus, Lifestream`s Chairman. "We value his wealth of experience within our market segment and his corporate management skills, as well as his passion for sound business judgment."

"Lifestream continues to prove the strength of its business model, and I hope to add value to the venture as it grows in scale and market penetration," said Siemens. "Clearly, the dynamics supporting cholesterol monitoring are strong and continue to be demonstrated through our marketing efforts on television shopping networks. I look forward to working with the board to help guide the Company as it expands."

Effective March 31, 2005, Siemens stepped down as Chief Operating Officer of Lifestream, a position he held since June 2002. Siemens will serve as a director until the next annual meeting of stockholders, at which time a director will be elected to fill the balance of the unexpired term of William R. Gridley, who resigned as a director on April 1, 2005.

About Lifestream Technologies

The Company developed and currently markets a line of cholesterol monitors to consumers and healthcare professionals that provide test results in three minutes.

Lifestream`s product line aids the health conscious consumer in monitoring their risk of heart disease. By regularly testing cholesterol at home, individuals can monitor the benefits of their diet, exercise and/or drug therapy programs. Monitoring these benefits can support the physician and the individual`s efforts to improve compliance. Lifestream`s products also integrate a smart card reader further supporting compliance by storing test results on an individual`s personal health card for future retrieval, trend analysis and assessment.

Lifestream`s monitors are affordable, hand-held devices that provide users with accurate results in less than three minutes. The product line has been designed to accommodate the Personal Health Card(R) allowing multiple users the ability to store their personal results. Lifestream`s products are now available in pharmacy and retail outlets nationwide. To find retailers that carry Lifestream`s products, go to "Store Locator" on www.knowitforlife.com or contact Customer Care at 888-954-LIFE. For Company information, visit www.lifestreamtech.com.

This news release includes certain forward-looking statements within the meaning of the safe harbor protections of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements regarding our current business plans, strategies and objectives that involve risks and uncertainties, and in particular statements referring to our expectations for increased market penetration and improved gross margins from our recently introduced second generation consumer monitors and statements regarding our expectations that we can obtain necessary additional financing and investment. These forward-looking statements involve risks and uncertainties that could cause actual results to differ from anticipated results. The forward-looking statements are based on our current expectations and what we believe are reasonable assumptions given our knowledge of the relevant markets; however, our actual performance, results and achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Factors, within and beyond our control, that could cause or contribute to such differences include, among others, the following: the success of our capital-raising and cost-cutting efforts, developing and marketing relatively new medical diagnostic devices, including technological advancements and innovations; consumer receptivity and preferences; availability, affordability and coverage terms of private and public medical insurance; political and regulatory environments and general economic and business conditions; the effects of our competition; the success of our operating, marketing and growth initiatives; development and operating costs; the amount and effectiveness of our advertising and promotional efforts; brand awareness; the existence of adverse publicity; changes in business strategies or development plans; quality and experience of our management; availability, terms and deployment of capital; labor and employee benefit costs; as well as those factors discussed in our most recent Registration Statement on Form SB-2 filed March 7, 2005, and in "Item 1 -- Business," "Item 6 -- Management`s Discussion and Analysis or Plan of Operation," particularly the discussion under "Risk Factors -- Substantial Doubt regarding our Ability to Continue as a Going Concern" and elsewhere in our most recent Annual Report on Form 10-KSB for our fiscal year ended June 30, 2004, both filed with the United States Securities and Exchange Commission. Readers are urged to carefully review and consider the various disclosures made by us in this report, in the aforementioned Form SB-2 and Form 10-KSB, and those detailed from time to time in our other reports and filings with the United States Securities and Exchange Commission that attempt to advise interested parties of the risks and factors that are likely to affect our business.


CONTACT: Lifestream Technologies, Inc.Gerri Vance, 208-457-9409 ext. 1221

SOURCE: Lifestream Technologies, Inc.

Der Kurs läßt sich momentan von Meldungen nicht beeintrucken, und marschiert in Richtung Süden.

Momentan stehen wir bei $ 0,016.

[connyco]

Pssst, der Letzte macht das Licht aus !!

[Inkmarker]

LFTC: Default on Payment Triggers Demand by Debenture Holder



Lifestream Technologies (LFTC) announced that it failed to make a required $100,000 payment of principal on its outstanding promissory note in the aggregate principal amount of $2,869,740 payable to RAB Special Situations LP (“RAB”). Under the terms of the note, in the event of a default in payment obligations under the note, the entire principal amount of the note becomes immediately due and payable. Palisades Master Fund L.P. has alleged that by reason of the Company`s failure to make the May 1, 2005 installment payment to RAB, the Company has defaulted on its obligations under a convertible debenture previously issued in favor of Palisades. Palisades has demanded the sum of $1,650,000, allegedly representing the original principal amount of the debenture issued to Palisades. The Company has rejected Palisade`s demand.

[Saftladen]

was denn nun

[connyco]

verkaufen -sofern überhaupt noch jemand kauft !!-- solange der VK-Erlös noch höher ist als die Verkaufsgebühren

[DonTyson11]

ne typische inkmarker empfehlung

[Saftladen]

in berlin

bid 120000 stück zu 0,01
ask 100000 stück zu 0,02

[Inkmarker]

#109

Selbst zum Lesen ist unser Möchte-gern-Porno-Star zu dumm, denn ansonsten hätte selbst jemand mit einem derart beschränkten Geist, wie unser Don, gemerkt, dass ich am Anfang des Threads auf die Risiken aufmerksam gemacht haben.

Na ja, wahrscheinlich wird sein ganzes Blut aus dem Gehirn in seinen kleinen Schw... abgepumpt, was schon einiges über die Größe seines Gehirns sagt.



Wenn man es aufbläst, kommt immehin auf Erbsengröße. Aber beim Blasen, denkt unser Schwanzunsminimus natürlich an etwas ganz anderes.



Für alle, die mal richtig ablachen wollen:

Thread: Wie Schaffe ich den Einstieg in meinen Traumberuf

[Saftladen]

seid lieb

[Chris8888]

@alle,


wie seht ihr das...Habe noch 75k und weiß nicht ob ich sie halten soll!Was ist von Lifestream in den kommenden Jahren noch zu erwarten?Danke für viele,vernüftige Antworten!!

Chris

[Inkmarker]

@Chris,

die Entwicklung der kommenden Jahre hängt m.E. entscheidend davon ab, was mit der ausstehenden Wandelanleihe wird.

Zuletzt konnte diese ja schon nicht bedient werden.

Das Geschäftsfeld ist sicher durchaus interessant; allerdngs beunruhigt mich der stetige Anstieg der ausgegebenen Aktien.

Wenn Du mit deinen Aktien noch innerhalb der Spekulationsfrist liegst, würde ich über einen Verkauf nachdenken. Ansonsten würde ich sie weiter halten, und hoffen, dass das die Gesellschaft den Durchbruch schafft.

Grüße Inkmarker

[Chris8888]

Danke Inkmaker,

bin sowieso im Minus,also mit Spekufrist egal!Wann entscheidet sich das denn mit der Wandelanleihe und war nicht im Jan05 so eine Anhörung bezüglich OvertheCounter Sales solcher Meßgeräte?
Ich meine die wurde Ergebnislos beendet,oder?
Verkaufst Du oder Die anderen hier denn?

MfG


Chris

[Inkmarker]

@Chris!

1. Die Wandelanleihe wird meines Wissens 2006 fällig. Dies steht am Anfang des Threads, als ich damals die Adhoc-Mitteilung übersetzt habe.

2. Die Anhörung Anfang 2005 war meines Wissens vor der FDA, und bezog sich im allgemeinen darauf, ob Cholesterinsenker unbeschränkt frei verkauft werden dürfen, was mit 20:3 Stimmen abgelehnt wurde. Folglich war LFTC nur indirekt davon betroffen.

3. Da bei mir die Spek.-frist schon abgelaufen ist, bleib ich weiter drin.


Gruß Inkmarker

[DonTyson11]

welch schöne empfehlung inkmarker

[Inkmarker]

@Don,

wenn Du lesen könntest, hättest Du erkannt, dass es sich hier um ein Diskussionsforum und nicht um eine Empfehlung gehandelt hat.

Aber sicherlich hast Du posting #1 geistig nicht erfasst.

[cyba]

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…

8K von heute...

da laesst sich einer in aktien bezahlen denke das ist ein positives signal! daher auch der kursanstieg heute...

[Chris8888]

@ alle,

sorry, muß aber mal die Frage stellen, da mein Englisch für die Erklärungen nicht ausreichend ist: Was haben diese 8k /10k ,oder ich glaube auch schon mal von einem 16k Filling gelesen zu haben, eigentlich zu bedeuten?


Lieben Dank

[Chris8888]

Hallo nochmal,

ich werfe nochmal die Fragen in den Raum, mit der Bitte um eine Antwort!

1)Was genau bedeuten die aufgenommenen Wandelanleihen? Soryy,das ich hier Lücken haben, aber ich komme eher aus der Medizin als aus dem BWLèr Bereich!!
2)Meint ihr, das die Firma mit dem neuen Finanzchef nochmals auferstehen wird oder eher nicht?


MfG


Chris

[connyco]

# 121
Die Firma ist so tot wie dieses Bord !!!

[Saftladen]